<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">PLoS</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21468300</article-id><article-id pub-id-type="pmc">3066129</article-id><article-id pub-id-type="publisher-id">PMEDICINE-D-10-00218</article-id><article-id pub-id-type="doi">10.1371/journal.pmed.1001015</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subject>Global Health</subject><subject>Infectious Diseases</subject><subject>Obstetrics and Gynecology</subject><subject>Pediatrics</subject><subject>Public Health</subject><subject>Women's Health</subject></subj-group></article-categories><title-group><article-title>Triple-Antiretroviral Prophylaxis to Prevent Mother-To-Child HIV
Transmission through Breastfeeding&#x02014;The Kisumu Breastfeeding Study, Kenya:
A Clinical Trial</article-title><alt-title alt-title-type="running-head">Prevention of HIV Transmission during
Breastfeeing</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Timothy K.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Masaba</surname><given-names>Rose</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Borkowf</surname><given-names>Craig B.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ndivo</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zeh</surname><given-names>Clement</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Misore</surname><given-names>Ambrose</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Otieno</surname><given-names>Juliana</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jamieson</surname><given-names>Denise</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Thigpen</surname><given-names>Michael C.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bulterys</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Slutsker</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>De Cock</surname><given-names>Kevin M.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Amornkul</surname><given-names>Pauli N.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Greenberg</surname><given-names>Alan E.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fowler</surname><given-names>Mary Glenn</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><collab>for the KiBS Study Team</collab><xref ref-type="author-notes" rid="fn1">
<sup>&#x000b6;</sup>
</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Division of HIV/AIDS Prevention, US Centers for Disease Control and
Prevention (CDC), Atlanta, Georgia, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Kenya Medical Research Institute (KEMRI)/CDC, Kisumu, Kenya</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Kenya Medical Research Institute, Kisumu, Kenya</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Provincial Medical Office - Nyanza Province, Ministry of Health, Kisumu,
Kenya</addr-line></aff><aff id="aff5"><label>5</label><addr-line>New Nyanza Provincial General Hospital, Kisumu, Kenya</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Division of Global HIV/AIDS, Center for Global Health, CDC, Atlanta,
Georgia, United States of America</addr-line></aff><aff id="aff7"><label>7</label><addr-line>Division of Parasitic Diseases, CDC, Atlanta, Georgia, United States of
America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Mofenson</surname><given-names>Lynne</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">National Institute of Child Health and Human Development, United States
of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>tft5@cdc.gov</email></corresp><fn fn-type="con"><p>
<ext-link ext-link-type="uri" xlink:href="http://www.icmje.org/">ICMJE</ext-link> criteria for authorship read and met: PNA CBB MB KMD
MGF AEG DJ AM RM RN JO MCT LS TKT CZ. Agree with the manuscript's
results and conclusions: PNA CBB MB KMD MGF AEG DJ AM RM RN JO MCT LS TKT
CZ. Enrolled patients: RM. Conceived and designed the experiments: PNA MB
KMD MGF AEG AM JO LS TKT. Performed the experiments: PNA CBB DJ RM RN MCT
TKT CZ. Analyzed the data: CBB MB KMD MGF AEG RM RN TKT CZ. Contributed
reagents/materials/analysis tools: CBB MB KMD MGF AEG RM RN TKT CZ. Wrote
the first draft of the paper: PNA CBB MB KMD MGF AEG RM RN MCT LS TKT.
Contributed to the writing of the paper: PNA CBB MB KMD MGF AEG RM RN MCT LS
TKT. Statistical analyses: CBB.</p></fn><fn id="fn1" fn-type="other"><p>&#x000b6; Membership of the KiBS Study Team is provided in the
Acknowledgments.</p></fn></author-notes><pub-date pub-type="collection"><month>3</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>29</day><month>3</month><year>2011</year></pub-date><volume>8</volume><issue>3</issue><elocation-id>e1001015</elocation-id><history><date date-type="received"><day>30</day><month>9</month><year>2010</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2011</year></date></history><permissions><copyright-statement>This is an open-access article, free of all copyright, and may be
freely reproduced, distributed, transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made available under the Creative
Commons CC0 public domain dedication.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</license-p></license></permissions><related-article related-article-type="companion" id="d35e356" vol="8" page="e1000430" issue="3" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="21468304" ext-link-type="pubmed"><article-title>HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to
HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral
Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary
Analysis</article-title></related-article><abstract abstract-type="toc"><p>Timothy Thomas and colleagues report the results of the Kisumu breastfeeding
study (Kenya), a single-arm trial that assessed the feasibility and safety of a
triple-antiretroviral regimen to suppress maternal HIV load in late
pregnancy.</p></abstract><abstract><sec><title>Background</title><p>Effective strategies are needed for the prevention of mother-to-child HIV
transmission (PMTCT) in resource-limited settings. The Kisumu Breastfeeding
Study was a single-arm open label trial conducted between July 2003 and
February 2009. The overall aim was to investigate whether a maternal
triple-antiretroviral regimen that was designed to maximally suppress viral
load in late pregnancy and the first 6 mo of lactation was a safe,
well-tolerated, and effective PMTCT intervention.</p></sec><sec><title>Methods and Findings</title><p>HIV-infected pregnant women took zidovudine, lamivudine, and either
nevirapine or nelfinavir from 34&#x02013;36 weeks' gestation to 6 mo post
partum. Infants received single-dose nevirapine at birth. Women were advised
to breastfeed exclusively and wean rapidly just before 6 mo. Using
Kaplan-Meier methods we estimated HIV-transmission and death rates from
delivery to 24 mo. We compared HIV-transmission rates among subgroups
defined by maternal risk factors, including baseline CD4 cell count and
viral load.</p><p>Among 487 live-born, singleton, or first-born infants, cumulative
HIV-transmission rates at birth, 6 weeks, and 6, 12, and 24 mo were
2.5&#x00025;, 4.2&#x00025;, 5.0&#x00025;, 5.7&#x00025;, and 7.0&#x00025;,
respectively. The 24-mo HIV-transmission rates stratified by baseline
maternal CD4 cell count &#x0003c;500 and &#x02265;500 cells/mm<sup>3</sup> were
8.4&#x00025; (95&#x00025; confidence interval [CI]
5.8&#x00025;&#x02013;12.0&#x00025;) and 4.1&#x00025;
(1.8&#x00025;&#x02013;8.8&#x00025;), respectively
(<italic>p</italic>&#x0200a;=&#x0200a;0.06); the corresponding rates
stratified by baseline maternal viral load &#x0003c;10,000 and &#x02265;10,000
copies/ml were 3.0&#x00025; (1.1&#x00025;&#x02013;7.8&#x00025;) and 8.7&#x00025;
(6.1&#x00025;&#x02013;12.3&#x00025;), respectively
(<italic>p</italic>&#x0200a;=&#x0200a;0.01). None of the 12 maternal
and 51 infant deaths (including two second-born infants) were attributed to
antiretrovirals. The cumulative HIV-transmission or death rate at 24 mo was
15.7&#x00025; (95&#x00025; CI 12.7&#x00025;&#x02013;19.4&#x00025;).</p></sec><sec><title>Conclusions</title><p>This trial shows that a maternal triple-antiretroviral regimen from late
pregnancy through 6 months of breastfeeding for PMTCT is safe and feasible
in a resource-limited setting. These findings are consistent with those from
other trials using maternal triple-antiretroviral regimens during
breastfeeding in comparable settings.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00146380">NCT00146380</ext-link>
</p></sec><sec><title/><p>
<italic>Please see later in the article for the Editors' Summary</italic>
</p></sec></abstract><abstract abstract-type="editor"><title>Editors' Summary</title><sec id="s5a1"><title>Background</title><p>Every year, about half a million children become infected with human
immunodeficiency virus (HIV), which causes acquired immunodeficiency
syndrome (AIDS). Nearly all these newly infected children live in
resource-limited countries and most acquire HIV from their mother, so-called
mother-to-child transmission (MTCT). Without intervention,
25&#x00025;&#x02013;50&#x00025; of babies born to HIV-positive mothers become
infected with HIV during pregnancy, delivery, or breastfeeding. This
infection rate can be reduced by treating mother and child with
antiretroviral (ARV) drugs. A single dose of nevirapine (a
&#x0201c;non-nucleoside reverse transcriptase inhibitor&#x0201d; or NNRTI) given
to the mother at the start of labor and to her baby soon after birth nearly
halves the risk of MTCT. Further reductions in risk can be achieved by
giving mother and baby three ARVs&#x02014;an NNRTI and two nucleoside reverse
transcriptase inhibitors (NRTIs such as zidovudine and
lamivudine)&#x02014;during pregnancy and perinatally (around the time of
birth).</p></sec><sec id="s5a2"><title>Why Was This Study Done?</title><p>Breastfeeding is crucial for child survival in poor countries but it is also
responsible for up to half of MTCT. Consequently, many researchers are
investigating how various ARV regimens given to mothers and/or their infants
during the first few months of life as well as during pregnancy and
perinatally affect MTCT. In this single-arm trial, the researchers assess
the feasibility and safety of using a triple-ARV regimen to suppress the
maternal HIV load (amount of virus in the blood) from late pregnancy though
6 months of breastfeeding among HIV-positive women in Kisumu, Kenya, and ask
whether this approach achieves a lower HIV transmission rate than other ARV
regimens that have been tested in resource-limited settings. In a single-arm
trial, all the participants are given the same treatment. By contrast, in a
&#x0201c;randomized controlled&#x0201d; trial, half the participants chosen at
random are given the treatment under investigation and the rest are given a
control treatment. A randomized controlled trial provides a better
comparison of treatments than a single-arm trial but is more costly.</p></sec><sec id="s5a3"><title>What Did the Researchers Do and Find?</title><p>In the Kisumu Breastfeeding Study (KiBS), HIV-infected pregnant women took a
triple-ARV regimen containing zidovudine and lamivudine and either
nevirapine or the protease inhibitor nelfinavir from 34&#x02013;36 weeks of
pregnancy to 6 months after delivery. They were advised to breastfeed their
babies (who received single-dose nevirapine at birth), and to wean them
rapidly just before 6 months. The researchers then used Kaplan-Meier
statistical methods to estimate HIV transmission and death rates among 487
live-born infants from delivery to 24 months. The cumulative HIV
transmission rate rose from 2.5&#x00025; at birth to 7.0&#x00025; at 24
months. The cumulative HIV transmission or death rate at 24 months was
15.7&#x00025;; no infant deaths were attributed to ARVs. At 24 months,
3.0&#x00025; of babies born to mothers with a low viral load were HIV
positive compared to 8.7&#x00025; of babies born to mothers with a high viral
load, a statistically significant difference. Similarly, at 24 months,
8.4&#x00025; of babies born to mothers with low baseline CD4 cell counts (CD4
cells are immune system cells that are killed by HIV; CD4 cell counts
indicate the level of HIV-inflicted immune system damage) were HIV positive
compared to 4.1&#x00025; of babies born to mothers with high baseline CD4
cell counts, although this difference did not achieve statistical
significance.</p></sec><sec id="s5a4"><title>What Do These Findings Mean?</title><p>Although these findings are limited by the single-arm design, they support
the idea that giving breastfeeding women a triple-ARV regimen from late
pregnancy to 6 months is a safe, feasible way to reduce MTCT in
resource-limited settings. The HIV transmission rates in this study are
comparable to those recorded in similar trials in other resource-limited
settings and are lower than MTCT rates observed previously in Kisumu in a
study in which no ARVs were used. Importantly, the KiBS mothers took most of
the ARVs they were prescribed and most stopped breastfeeding by 6 months as
advised. The intense follow-up employed in KiBS may be partly responsible
for this good adherence to the trial protocol and thus this study's
findings may not be generalizable to all resource-limited settings.
Nevertheless, they suggest that a simple triple-ARV regimen given to
HIV-positive pregnant women regardless of their baseline CD4 cell count can
reduce MTCT during pregnancy and breastfeeding in resource-limited
setting.</p></sec><sec id="s5a5"><title>Additional Information</title><p>Please access these Web sites via the online version of this summary at
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1001015">http://dx.doi.org/10.1371/journal.pmed.1001015</ext-link>.</p><list list-type="bullet"><list-item><p>The accompanying <italic>PLoS Medicine</italic>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000430">Research article by Zeh and colleagues</ext-link> describes the
emergence of resistance to ARVs in KiBS</p></list-item><list-item><p>
<ext-link ext-link-type="uri" xlink:href="http://www3.niaid.nih.gov/topics/HIVAIDS">Information on HIV and AIDS</ext-link> is available from the US National
Institute of Allergy and Infectious Diseases
</p></list-item><list-item><p>
<ext-link ext-link-type="uri" xlink:href="http://hivinsite.ucsf.edu">HIV InSite</ext-link> has comprehensive information on all
aspects of HIV/AIDS</p></list-item><list-item><p>Information is available from <ext-link ext-link-type="uri" xlink:href="http://www.avert.org">Avert</ext-link>, an
international AIDS charity, on many aspects of HIV/AIDS, including
information on <ext-link ext-link-type="uri" xlink:href="http://www.avert.org/children.htm">children, HIV,
and AIDS</ext-link> and on <ext-link ext-link-type="uri" xlink:href="http://www.avert.org/motherchild.htm">preventing
mother-to-child transmission of HIV</ext-link> (in English and
Spanish)</p></list-item><list-item><p>UNICEF also has information about <ext-link ext-link-type="uri" xlink:href="http://www.unicef.org/aids">children and HIV and
AIDS</ext-link> (in several languages)</p></list-item><list-item><p>The World Health organization has information on mother-to-child
transmission of HIV <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/topics/mtct/en/index.html">http://www.who.int/hiv/topics/mtct/en/index.html</ext-link> (in
several languages)</p></list-item></list></sec></abstract><counts><page-count count="12"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>UNAIDS and the World Health Organization (WHO) estimate that in 2009 there were
230,000 to 510,000 new HIV infections worldwide among children aged 0&#x02013;15 y of
age <xref rid="pmed.1001015-UNAIDS1" ref-type="bibr">[1]</xref>. Over
95&#x00025; of these infections occurred in resource-limited settings, primarily
sub-Saharan Africa. Most infections resulted from mother-to-child transmission
(MTCT). HIV MTCT rates in the absence of any antiretroviral (ARV) intervention among
breastfeeding mothers who tested HIV antibody positive during pregnancy or delivery
have ranged from 25&#x00025; to 48&#x00025; in various studies <xref rid="pmed.1001015-DeCock1" ref-type="bibr">[2]</xref>. Breastfeeding, which is crucial
to infant survival in resource-limited settings, accounts for one-third to one-half
of MTCT <xref rid="pmed.1001015-VandePerre1" ref-type="bibr">[3]</xref>&#x02013;<xref rid="pmed.1001015-Bulterys1" ref-type="bibr">[5]</xref>. Several trials of short-course/single-dose peripartum ARV
regimens have reported 18-mo transmission rates between 6.8&#x00025; and 15.9&#x00025;
<xref rid="pmed.1001015-The1" ref-type="bibr">[6]</xref>&#x02013;<xref rid="pmed.1001015-Jackson1" ref-type="bibr">[8]</xref>. However, in
most of these studies, transmission events occurred while the infants were
breastfeeding and not prophylaxed by maternal or infant ARVs <xref rid="pmed.1001015-Leroy1" ref-type="bibr">[9]</xref>.</p><p>For HIV-infected pregnant women in situations where replacement infant foods are not
affordable, feasible, accessible, safe, and sustainable (AFASS conditions), 1998 WHO
guidelines <xref rid="pmed.1001015-WHO1" ref-type="bibr">[10]</xref>
encouraged exclusive breastfeeding for the first months of life followed by rapid
weaning. Revised 2006 guidelines <xref rid="pmed.1001015-WHO2" ref-type="bibr">[11]</xref> recommended that AFASS conditions should be reassessed
with the mother at 6 mo, and if not met, breastfeeding should continue with the
introduction of complementary feeding.</p><p>In recognition of both the benefits and risks of breastfeeding for HIV-exposed
infants, several trials have been conducted over the last decade to assess the
impact on prevention of MTCT (PMTCT) of various combinations of ARV regimens given
to mother and/or infant. We conducted the Kisumu Breastfeeding Study (KiBS) in
Kisumu, Kenya; a PMTCT single-arm trial using a maternal triple-ARV regimen given to
HIV-infected pregnant women beginning at 34 wk gestation and continuing for up to 6
mo post partum while exclusively breastfeeding. The primary objective of this trial
was to assess whether the regimen was feasible, well tolerated, safe, and achieved a
lower transmission rate compared to other short-course regimens evaluated among
breastfeeding mothers in resource-limited settings.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>KiBS was a phase IIB open-label single-arm clinical/intervention trial approved by
the ethical review committees of KEMRI (protocol 691) and US CDC (protocol 3677).
See Protocol (<xref ref-type="supplementary-material" rid="pmed.1001015.s001">Text
S1</xref>) and CONSORT statement (<xref ref-type="supplementary-material" rid="pmed.1001015.s002">Text S2</xref>).</p><sec id="s2a"><title>Primary Objectives</title><p>The primary objectives of this study using maternal triple-ARV for PMTCT in late
pregnancy and during breast feeding were the following: (1) to detect a
50&#x00025; reduction in the mother-to-child HIV-transmission rate at 18 mo
compared to the corresponding rate using the single-dose nevirapine (NVP)
regimen in the HIVNET 012 study <xref rid="pmed.1001015-Jackson1" ref-type="bibr">[8]</xref>; (2) to detect a 50&#x00025;
improvement in the infant HIV-free survival rate at 18 mo compared to the
corresponding rate using the single-dose NVP regimen in the HIVNET 012 study
<xref rid="pmed.1001015-Jackson1" ref-type="bibr">[8]</xref>; (3)
to assess safety and toxicity for the mothers with use of the maternal
triple-ARV prophylaxis particularly regarding rates of hepatic, hematologic, or
dermatologic toxicities; (4) to assess adverse events or evidence of hepatic,
hematologic, or dermatologic toxicity for infants exposed to low dose ARVs
through maternal breast milk.</p></sec><sec id="s2b"><title>Participants</title><p>Enrollment was conducted between July 2003 and November 2006; follow-up was
completed in February 2009. Women were recruited through the PMTCT programs in
the antenatal clinics of the New Nyanza Provincial General Hospital and the
Kisumu District Hospital, both serving lower income populations of Kisumu and
its environs. Pregnant women were invited to enroll if they were HIV positive
and if, after receiving risk-benefit counseling on infant feeding options, they
indicated intent to breastfeed. Enrollment criteria included: age &#x02265;15 y,
gestation of 34&#x02013;36 wk, no previous ARV exposure, hemoglobin (Hb) &#x02265;7
g/dl, absolute neutrophil count (ANC) &#x0003e;1,000 cells/mm<sup>3</sup>, platelets
&#x0003e;50,000/ml, creatinine &#x0003c;1.5 mg/dl, and serum alanine aminotransferase
(ALT) &#x0003c;2.5 times upper limit of normal.</p></sec><sec id="s2c"><title>Procedures</title><p>Potential participants provided written informed consent, and at 32&#x02013;34 wk
gestation they underwent screening evaluations, which included a medical
history, a physical examination, laboratory confirmation of HIV status, complete
blood count, CD4 cell count, creatinine, and ALT tests. Participants started the
triple-ARV regimen at 34&#x02013;36 wk gestation and continued while
breastfeeding, until 6 mo post partum. The initial regimen consisted of two
nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse
transcriptase inhibitor. Between July 2003 and January 2005, regardless of CD4
cell count, mothers received zidovudine (ZDV) 300 mg and lamivudine (3TC) 150 mg
in a fixed-dose combination pill (Combivir, GlaxoSmithKline), taken twice daily,
and NVP 200 mg (Viramune, Boehringer Ingelheim), once daily for the first 2 wk
and then twice daily thereafter. In January 2005, enrollment was halted because
of reports of hepatotoxicity among women who started taking NVP when their CD4
count was &#x02265;250 cells/mm<sup>3</sup>
<xref rid="pmed.1001015-Boehringer1" ref-type="bibr">[12]</xref>.
Enrollment resumed in July 2005 with a revised regimen; women with a baseline
CD4 count of &#x02265;250 cells/mm<sup>3</sup> received nelfinavir (NFV) (Viracept,
Hoffman-La Roche Ltd) 1,250 mg (five 250 mg pills) twice daily instead of NVP.
The decision to use NFV as an alternative ARV was based on the safety data
available at that time and appropriateness of use in resource-limited settings.
All women who met WHO treatment criteria (CD4 count of &#x0003c;200
cells/mm<sup>3</sup> or WHO stage 3 or 4) <xref rid="pmed.1001015-WHO3" ref-type="bibr">[13]</xref> at enrollment or before 6 mo
post partum remained on ARVs throughout the study; those who subsequently met
WHO treatment criteria after stopping ARVs at 6 mo were restarted on treatment
ARVs. Upon exiting the study, all participants were referred to facilities
providing HIV care and treatment, including free ARVs. All women received
trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of opportunistic
infections throughout the study, except from 38 wk gestation until delivery
because of concerns about neonatal hyperbilirubinemia.</p><p>Infants received single dose NVP (2 mg/kg) within 72 h of birth and TMP/SMX from
6 wk of age until they were no longer exposed to HIV through breastfeeding and
were confirmed to be HIV negative. HIV-infected infants began ARV treatment when
they met WHO infant treatment criteria <xref rid="pmed.1001015-WHO3" ref-type="bibr">[13]</xref>.</p><p>Women were counseled to exclusively breastfeed for the first 5.5 mo and then to
wean over 2 wk, with complete cessation of breastfeeding by 6 mo. We encouraged
use of locally available foods (e.g., porridge, soups), and cow's milk for
weaning and replacement feeding. We did not consider evaluating formula as a
PMTCT intervention in accordance with guidance from the Provincial Ministry of
Health about the risks of formula feeding, and in light of evidence of poor
acceptance of free formula provided by UNICEF in Kenya <xref rid="pmed.1001015-Rutenberg1" ref-type="bibr">[14]</xref>.</p><p>Before delivery, participants were evaluated weekly. After delivery, each mother
and her infant(s) were followed for 24 mo: study visits were scheduled at
delivery (0&#x02013;7 d), 2, 6, 10, and 14 wk post partum, and 6, 9, 12, 15, 18,
and 24 mo post partum. Three visits were added at 5, 7, and 8 mo to monitor
infant weight around weaning. During study visits, we assessed adherence to
drugs and infant feeding recommendations, performed clinical evaluations, and
obtained blood for hematologic, biochemical, and virologic monitoring. Adherence
to study ARVs was assessed through pill counts, calculated as the percentage of
pills dispensed but not returned out of the total number of pills dispensed. The
study provided or covered the cost for all outpatient and inpatient care
required by participants while on study.</p><p>All laboratory testing was done at the KEMRI/CDC laboratory in Kisumu.
Hematologic testing was done using a Coulter A<sup>c</sup>.T 5diff CP analyzer
(Beckman Coulter). Lymphocyte subsets were analyzed on a FACSCalibur flow
cytometer (Becton Dickinson). Biochemistry analysis was done using the Cobas
Integra 400 plus biochemistry analyzer (Roche). Plasma viral loads were
quantified using the Amplicor HIV-1 RNA Monitor Test v1.5 (Roche Diagnostics).
HIV DNA testing by PCR was done using Amplicor HIV-1 DNA PCR assay v1.5 (Roche
Diagnostics). ELISA was done using Vironostika HIV Uniform II plus O kit
(Organon Teknika) and Enzygnost (Dade Behring Marburg GmbH).</p><p>For HIV testing of infants we used dried blood spots collected at birth
(0&#x02013;7 d), at 2, 6, and 14 wk, and at 6, 9, 12, 18, and 24 mo. DNA PCR
testing was performed in real time on the 14-wk and 6- and 9-mo specimens. ELISA
was performed at 18 and 24 mo, with confirmation of positive results by PCR.
After any positive test result, PCR testing was performed sequentially on prior
untested specimens in order to identify the first positive specimen.</p><p>We graded adverse events according to the 1992 Adult and 1994 Pediatric toxicity
tables <xref rid="pmed.1001015-NIH1" ref-type="bibr">[15]</xref>,<xref rid="pmed.1001015-NIH2" ref-type="bibr">[16]</xref> of the
Division of AIDS (DAIDS), US National Institutes of Health (NIH). Serious
adverse events (SAEs) were defined as grade 3 or 4 toxicity confirmed on a
repeat visit or as illness resulting in death or hospitalization. In addition,
grade 2 hepatotoxicity events and grade 2 rashes with signs of hypersensitivity
reaction were classified as SAEs. SAEs that occurred while participants were
taking ARVs or within 3 mo of their cessation were considered possibly related
to an ARV if an increased risk was noted in the prescribing information for the
drug <xref rid="pmed.1001015-Boehringer2" ref-type="bibr">[17]</xref>,<xref rid="pmed.1001015-GlaxoSmithKline1" ref-type="bibr">[18]</xref> or if no
alternative cause could be found. We did not rechallenge participants with the
potentially causative ARV. We confine this analysis to those SAEs occurring
between enrollment and 9 mo post partum. Abnormal laboratory findings were
confirmed prior to any change in ARV regimen. Causes of death were determined by
review of hospital records (if available) and/or by interviewing the mother,
spouse, or caretaker (verbal autopsy).</p></sec><sec id="s2d"><title>Statistical Analysis</title><p>We performed a series of sample size and power calculations under a variety of
assumptions. Historically, the cumulative HIV-transmission rate in the NVP arm
of the HIVNET 012 study <xref rid="pmed.1001015-Jackson1" ref-type="bibr">[8]</xref> was 11.8&#x00025; at 6 wk and 15.7&#x00025; at 18 mo of
age. We wanted to be able to detect a 50&#x00025; reduction in the corresponding
rate in KiBS using a one-sided exact binomial test at the 0.025 significance
level, as an approximation to the test based on the Kaplan-Meier function for
low rates. For 95&#x00025; statistical power, if the true HIV-transmission rate
in KiBS was 8&#x00025;, 9&#x00025;, or 10&#x00025;, then 225, 305, or 425 children,
respectively, would be needed for analysis at 18 mo of age. We further inflated
these sample sizes by a factor of 1/(1&#x02212;0.2) to account for maternal and
child drop-out, as well as other sources of heterogeneity, thus giving a
required maternal enrolment of 282, 382, or 532, respectively. Standard summary
statistics were used to describe sociodemographic, clinical, laboratory,
delivery, and adherence data. All statistical calculations were performed using
SAS statistical software (SAS Institute).</p><p>For the evaluation of HIV transmission we included only live-born singleton or
first-born infants who had any HIV test data. For our purposes,
&#x0201c;first-born&#x0201d; means the first infant born in a multiple birth (e.g.,
the first twin). For infants testing HIV positive, the time of HIV transmission
was estimated as the midpoint between the last negative and first positive test
result. All infants with PCR-positive samples before 7 d of age were assumed to
have been born infected. We used the Kaplan-Meier method to estimate
HIV-transmission rates, death rates, and combined HIV-transmission or death
rates over the 2-y follow-up period, and constructed 95&#x00025; confidence
interval (CIs) using the log-log transformation. We included all infants
regardless of maternal adherence to intervention or maternal death. Serial
pregnancies were not included.</p><p>For the HIV-transmission analysis, the endpoint was the estimated time of HIV
transmission or was censored at the last negative test result. For the death
analysis, the endpoint was the time of death or was censored at the last time
observed alive. For the combined HIV transmission or death analysis, the
endpoint was estimated HIV-transmission time, or death time (if not HIV
infected), or was censored at the last negative test result.</p><p>In addition, we stratified the HIV-transmission rates by selected variables of
interest, including study period (i.e., before or after the introduction of NFV
in July 2005), infant gender, maternal baseline CD4 count and viral load, and
maternal regimen for those with maternal baseline CD4 counts &#x02265;250
cells/mm<sup>3</sup>. We performed log-rank tests to compare the survival
curves obtained in these stratified analyses over the 2-y follow-up period. We
also used normal approximation methods to compare differences between the
Kaplan-Meier estimates of the stratified HIV-transmission rates at 24 mo.
Finally, we calculated relative risks (RRs) with 95&#x00025; CIs to determine
whether hepatotoxicity and rash SAEs were associated with baseline maternal CD4
counts (&#x0003c;250 and &#x02265;250 cells/mm<sup>3</sup>) among the 310 women whose
initial triple-ARV regimen included NVP.</p></sec></sec><sec id="s3"><title>Results</title><p>Between July 2003 and November 2006, we screened 602 HIV-positive women, recruited
from antenatal PMTCT clinics; 522 (87&#x00025;) met eligibility criteria and were
enrolled (<xref ref-type="fig" rid="pmed-1001015-g001">Figure 1</xref>). The main
reasons for ineligibility included being over 36 wk gestation (40&#x00025;), Hb&#x0003c;7
gm/dl (12&#x00025;), unable or unwilling to comply with study procedures
(18&#x00025;), HIV negative on confirmatory testing (9&#x00025;), delivered before
enrollment (8&#x00025;), other abnormal laboratory test (5&#x00025;), and other
reasons (8&#x00025;). The median age of those enrolled was 23 y (range 15&#x02013;43 y)
(<xref ref-type="table" rid="pmed-1001015-t001">Table 1</xref>). The median CD4
count was 398 cells/mm<sup>3</sup>; 74 (14&#x00025;) women had a CD4 count of &#x0003c;200
cells/mm<sup>3</sup>. NVP- or NFV-based triple-ARV prophylaxis was initiated in
310 women and 212 women respectively.</p><fig id="pmed-1001015-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001015.g001</object-id><label>Figure 1</label><caption><title>Recruitment, enrollment, and follow-up of participating women and
infants. KiBS, 2003&#x02013;2009.</title></caption><graphic xlink:href="pmed.1001015.g001"/></fig><table-wrap id="pmed-1001015-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001015.t001</object-id><label>Table 1</label><caption><title>Maternal baseline sociodemographic, clinical, and laboratory
characteristics.</title></caption><alternatives><graphic id="pmed-1001015-t001-1" xlink:href="pmed.1001015.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable
(<italic>n</italic>&#x0200a;=&#x0200a;522)</td><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">Number (&#x00025;) or Median (Range)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ethnic group</td><td align="left" rowspan="1" colspan="1">Luo</td><td align="left" rowspan="1" colspan="1">447 (86&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Luhya</td><td align="left" rowspan="1" colspan="1">54 (10&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">21 (4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median age (y)
(<italic>n</italic>&#x0200a;=&#x0200a;520)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">23 (15&#x02013;43)</td></tr><tr><td align="left" rowspan="1" colspan="1">Primigravid</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">130 (25&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">392 (75&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median parity, among multigravid
(<italic>n</italic>&#x0200a;=&#x0200a;392)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2 (0&#x02013;8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Marital status</td><td align="left" rowspan="1" colspan="1">Single</td><td align="left" rowspan="1" colspan="1">69 (13&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Married</td><td align="left" rowspan="1" colspan="1">388 (74&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Separated</td><td align="left" rowspan="1" colspan="1">26 (5&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Widowed</td><td align="left" rowspan="1" colspan="1">39 (8&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Living with child's father
(<italic>n</italic>&#x0200a;=&#x0200a;521)</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">376 (72&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">145 (28&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Completed primary education (8 y)</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">368 (70&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">154 (30&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Employed outside home</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">174 (33&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">348 (67&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median <italic>n</italic> people in household
(<italic>n</italic>&#x0200a;=&#x0200a;521)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3 (1&#x02013;14)</td></tr><tr><td align="left" rowspan="1" colspan="1">Access to water
(<italic>n</italic>&#x0200a;=&#x0200a;520)</td><td align="left" rowspan="1" colspan="1">Piped to house</td><td align="left" rowspan="1" colspan="1">26 (5&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Public tap</td><td align="left" rowspan="1" colspan="1">401 (77&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Well, borehole</td><td align="left" rowspan="1" colspan="1">59 (11&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">River, lake, rain</td><td align="left" rowspan="1" colspan="1">34 (7&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Toilet facility</td><td align="left" rowspan="1" colspan="1">Private/shared flush toilet</td><td align="left" rowspan="1" colspan="1">60 (11&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pit, latrine, bush</td><td align="left" rowspan="1" colspan="1">462 (89&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb (g/dl)
(<italic>n</italic>&#x0200a;=&#x0200a;520)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9.8 (7.0&#x02013;13.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median viral load (copies/ml)
(<italic>n</italic>&#x0200a;=&#x0200a;520)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">33,975 (0&#x02013;2.9 million)</td></tr><tr><td align="left" rowspan="1" colspan="1">Viral load (copies/ml)
(<italic>n</italic>&#x0200a;=&#x0200a;520)</td><td align="left" rowspan="1" colspan="1">Undetectable (&#x0003c;400)</td><td align="left" rowspan="1" colspan="1">27 (5&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">400&#x02013;9,999</td><td align="left" rowspan="1" colspan="1">120 (23&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10,000&#x02013;49,999</td><td align="left" rowspan="1" colspan="1">151 (29&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02265;50,000</td><td align="left" rowspan="1" colspan="1">222 (43&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median CD4 count (cells/mm<sup>3</sup>)
(<italic>n</italic>&#x0200a;=&#x0200a;520)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">398 (32&#x02013;1,340)</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 count (cells/mm<sup>3</sup>)
(<italic>n</italic>&#x0200a;=&#x0200a;520)</td><td align="left" rowspan="1" colspan="1">&#x0003c;200</td><td align="left" rowspan="1" colspan="1">74 (14&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">200&#x02013;349</td><td align="left" rowspan="1" colspan="1">130 (25&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">350&#x02013;499</td><td align="left" rowspan="1" colspan="1">144 (28&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02265;500</td><td align="left" rowspan="1" colspan="1">172 (33&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">WHO clinical HIV disease stage</td><td align="left" rowspan="1" colspan="1">Stage 1</td><td align="left" rowspan="1" colspan="1">439 (84&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Stage 2</td><td align="left" rowspan="1" colspan="1">45 (9&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Stage 3 or 4</td><td align="left" rowspan="1" colspan="1">38 (7&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial triple-ARV regimen</td><td align="left" rowspan="1" colspan="1">ZDV/3TC plus NVP</td><td align="left" rowspan="1" colspan="1">310 (59&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ZDV/3TC plus NFV</td><td align="left" rowspan="1" colspan="1">212 (41&#x00025;)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Percentages were computed excluding individuals with missing data for
that particular characteristic.
<italic>n</italic>&#x0200a;=&#x0200a;522 unless stated.</p></fn></table-wrap-foot></table-wrap><p>A total of 511 infants were delivered, including nine sets of twins and one set of
triplets (<xref ref-type="table" rid="pmed-1001015-t002">Table 2</xref>). There were
nine stillbirths (all singletons), resulting in 502 live births (275
[57&#x00025;] male, 227 [43&#x00025;] female). No specimens were
obtained from five infants (all males) who died within 1 wk of delivery. Overall,
457 (91&#x00025;), 427 (85&#x00025;), and 400 (80&#x00025;) live-born infants remained
in the study at 6, 12, and 24 mo, respectively (<xref ref-type="fig" rid="pmed-1001015-g001">Figure 1</xref>). There were 491 live-born singletons
and first borns.</p><table-wrap id="pmed-1001015-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001015.t002</object-id><label>Table 2</label><caption><title>Maternal and infant delivery characteristics.</title></caption><alternatives><graphic id="pmed-1001015-t002-2" xlink:href="pmed.1001015.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable
(<italic>n</italic>&#x0200a;=&#x0200a;500)</td><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic> (&#x00025;) or Median (Range)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Location of delivery</td><td align="left" rowspan="1" colspan="1">Hospital<xref ref-type="table-fn" rid="nt103">a</xref>
</td><td align="left" rowspan="1" colspan="1">392 (78&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Other health facility</td><td align="left" rowspan="1" colspan="1">22 (4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Participant's home</td><td align="left" rowspan="1" colspan="1">45 (9&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TBA home</td><td align="left" rowspan="1" colspan="1">30 (6&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Other/unknown</td><td align="left" rowspan="1" colspan="1">11 (2&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median gestation (wk)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">39 (33&#x02013;48)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gestation (wk)</td><td align="left" rowspan="1" colspan="1">&#x0003c;37</td><td align="left" rowspan="1" colspan="1">72 (14&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">37&#x02013;42</td><td align="left" rowspan="1" colspan="1">355 (71&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;42</td><td align="left" rowspan="1" colspan="1">73 (15&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median no. days on ARVs at delivery
(<italic>n</italic>&#x0200a;=&#x0200a;498)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">39 (1&#x02013;100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Days on ARVs at delivery
(<italic>n</italic>&#x0200a;=&#x0200a;498)</td><td align="left" rowspan="1" colspan="1">&#x0003c;28 d</td><td align="left" rowspan="1" colspan="1">130 (26&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02265;28</td><td align="left" rowspan="1" colspan="1">368 (74&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median viral load at delivery (copies/ml)
(<italic>n</italic>&#x0200a;=&#x0200a;497)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">87 (0&#x02013;1.1 million)</td></tr><tr><td align="left" rowspan="1" colspan="1">Viral load at delivery (copies/ml)
(<italic>n</italic>&#x0200a;=&#x0200a;497)</td><td align="left" rowspan="1" colspan="1">Undetectable (&#x0003c;400)</td><td align="left" rowspan="1" colspan="1">333 (67&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">400&#x02013;9,999</td><td align="left" rowspan="1" colspan="1">132 (27&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10,000&#x02013;49,999</td><td align="left" rowspan="1" colspan="1">11 (2&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02265;50,000</td><td align="left" rowspan="1" colspan="1">21 (4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Infants delivery characteristics (</bold>
<bold><italic>n</italic></bold>
<bold>&#x0200a;=&#x0200a;511)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Infant status</td><td align="left" rowspan="1" colspan="1">Live births</td><td align="left" rowspan="1" colspan="1">502</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Stillbirths</td><td align="left" rowspan="1" colspan="1">9 (all singletons)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Singletons</td><td align="left" rowspan="1" colspan="1">481</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Twins</td><td align="left" rowspan="1" colspan="1">18 (9 sets)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Triplets</td><td align="left" rowspan="1" colspan="1">3 (1 set)</td></tr><tr><td align="left" rowspan="1" colspan="1">Infant sex</td><td align="left" rowspan="1" colspan="1">Female (8 stillbirths)</td><td align="left" rowspan="1" colspan="1">235 (46&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Male (1 stillbirth)</td><td align="left" rowspan="1" colspan="1">276 (54&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Delivery method
(<italic>n</italic>&#x0200a;=&#x0200a;511)</td><td align="left" rowspan="1" colspan="1">Spontaneous vertex</td><td align="left" rowspan="1" colspan="1">386 (76&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Breech</td><td align="left" rowspan="1" colspan="1">8 (2&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cesarean delivery</td><td align="left" rowspan="1" colspan="1">41 (8&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Other/unknown</td><td align="left" rowspan="1" colspan="1">76 (15&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median infant birth weight (g)
(<italic>n</italic>&#x0200a;=&#x0200a;493)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3,000 (1,000&#x02013;4,700)</td></tr><tr><td align="left" rowspan="1" colspan="1">Infant birth weight (g)
(<italic>n</italic>&#x0200a;=&#x0200a;493)</td><td align="left" rowspan="1" colspan="1">&#x0003c;2,500</td><td align="left" rowspan="1" colspan="1">48 (10&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02265;2,500</td><td align="left" rowspan="1" colspan="1">420 (90&#x00025;)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>Percentages were computed excluding individuals with missing data for
that particular characteristic.</p></fn><fn id="nt103"><label>a</label><p>New Nyanza Provincial General Hospital and Kisumu District Hospital.</p></fn><fn id="nt104"><label/><p>TBA, traditional birth attendant.</p></fn></table-wrap-foot></table-wrap><sec id="s3a"><title>Transmission Rates</title><p>Among the 487 infants who ever had an HIV test, 12 had positive delivery samples
(0&#x02013;7 d), consistent with a transmission rate of 2.5&#x00025;
(1.4&#x00025;&#x02013;4.3&#x00025;) (<xref ref-type="table" rid="pmed-1001015-t003">Table 3</xref>). An additional eight infections occurred by 6 wk for a
cumulative transmission rate of 4.2&#x00025; (2.7&#x00025;&#x02013;6.4&#x00025;).
Cumulative transmission rates at 6, 12, 18, and 24 mo were 5.0&#x00025;
(3.4&#x00025;&#x02013;7.4&#x00025;), 5.7&#x00025; (4.0&#x00025;&#x02013;8.3&#x00025;),
6.7&#x00025; (4.8&#x00025;&#x02013;9.4&#x00025;), and 7.0&#x00025;
(5.0&#x00025;&#x02013;9.7&#x00025;), respectively (<xref ref-type="fig" rid="pmed-1001015-g002">Figure 2</xref>). Among 491 singleton or first-born
infants, the death rates at 6, 12, 18, and 24 mo were 3.7&#x00025;
(2.4&#x00025;&#x02013;5.9&#x00025;), 8.9&#x00025; (6.7&#x00025;&#x02013;11.9&#x00025;),
10.0&#x00025; (7.6&#x00025;&#x02013;13.1&#x00025;), and 10.4&#x00025;
(8.0&#x00025;&#x02013;13.6&#x00025;), respectively. Likewise, among these 491
infants, the combined HIV-transmission or death rates at 6, 12, 18, and 24 mo
were 8.5&#x00025; (6.3&#x00025;&#x02013;11.4&#x00025;), 13.5&#x00025;
(10.7&#x00025;&#x02013;16.9&#x00025;), 15.3&#x00025;
(12.3&#x00025;&#x02013;18.9&#x00025;), and 15.7&#x00025;
(12.7&#x00025;&#x02013;19.4&#x00025;), respectively. Conversely, HIV-free survival
at 24 mo was 84.3&#x00025; (80.6&#x00025;&#x02013;87.3&#x00025;).</p><fig id="pmed-1001015-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001015.g002</object-id><label>Figure 2</label><caption><title>Kaplan-Meier estimates of HIV-transmission rates.</title><p>Kaplan-Meier estimates of HIV-transmission rates among live-born
singletons and first-born infants of mothers who received triple-ARV
prophylaxis between 34 wk gestation and 6 mo post partum with 95&#x00025;
CIs.</p></caption><graphic xlink:href="pmed.1001015.g002"/></fig><table-wrap id="pmed-1001015-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001015.t003</object-id><label>Table 3</label><caption><title>Kaplan-Meier estimates of rates of HIV transmission and infant
death.</title></caption><alternatives><graphic id="pmed-1001015-t003-3" xlink:href="pmed.1001015.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">HIV Transmission
(<italic>n</italic>&#x0200a;=&#x0200a;487)</td><td colspan="3" align="left" rowspan="1">Infant Death
(<italic>n</italic>&#x0200a;=&#x0200a;491)</td><td colspan="3" align="left" rowspan="1">Combined Outcome
(<italic>n</italic>&#x0200a;=&#x0200a;491)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Events</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">Events</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">Events</td><td align="left" rowspan="1" colspan="1">Rate</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">7 d</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">(1.4&#x02013;4.3)</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">(0.7&#x02013;3.0)</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">(2.5&#x02013;6.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">14 d</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">(1.7&#x02013;4.8)</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;3.5)</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">4.7</td><td align="left" rowspan="1" colspan="1">(3.1&#x02013;7.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">30 d</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">(2.5&#x02013;6.1)</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;3.5)</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">(4.0&#x02013;8.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">42 d</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">4.2</td><td align="left" rowspan="1" colspan="1">(2.7&#x02013;6.4)</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">(1.3&#x02013;4.0)</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">6.4</td><td align="left" rowspan="1" colspan="1">(4.5&#x02013;8.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">2 m</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">4.2</td><td align="left" rowspan="1" colspan="1">(2.7&#x02013;6.4)</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">(1.3&#x02013;4.0)</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">6.4</td><td align="left" rowspan="1" colspan="1">(4.5&#x02013;8.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">3 m</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">4.6</td><td align="left" rowspan="1" colspan="1">(3.0&#x02013;6.9)</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">(1.4&#x02013;4.3)</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">7.0</td><td align="left" rowspan="1" colspan="1">(5.0&#x02013;9.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">4 m</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">4.6</td><td align="left" rowspan="1" colspan="1">(3.0&#x02013;6.9)</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">(1.7&#x02013;4.8)</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">7.4</td><td align="left" rowspan="1" colspan="1">(5.4&#x02013;10.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">6 m</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">5.0</td><td align="left" rowspan="1" colspan="1">(3.4&#x02013;7.4)</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">(2.4&#x02013;5.9)</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">8.5</td><td align="left" rowspan="1" colspan="1">(6.3&#x02013;11.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">9 m</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">5.5</td><td align="left" rowspan="1" colspan="1">(3.8&#x02013;8.0)</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">7.4</td><td align="left" rowspan="1" colspan="1">(5.4&#x02013;10.1)</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">12.2</td><td align="left" rowspan="1" colspan="1">(9.6&#x02013;15.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">12 m</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">(4.0&#x02013;8.3)</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">8.9</td><td align="left" rowspan="1" colspan="1">(6.7&#x02013;11.9)</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">13.5</td><td align="left" rowspan="1" colspan="1">(10.7&#x02013;16.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">18 m</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">6.7</td><td align="left" rowspan="1" colspan="1">(4.8&#x02013;9.4)</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">10.0</td><td align="left" rowspan="1" colspan="1">(7.6&#x02013;13.1)</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">15.3</td><td align="left" rowspan="1" colspan="1">(12.3&#x02013;18.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">24 m</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">7.0</td><td align="left" rowspan="1" colspan="1">(5.0&#x02013;9.7)</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">10.4</td><td align="left" rowspan="1" colspan="1">(8.0&#x02013;13.6)</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">15.7</td><td align="left" rowspan="1" colspan="1">(12.7&#x02013;19.4)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>Kaplan-Meier estimates of the cumulative rates of HIV transmission,
infant death, and combined HIV transmission or death at selected
ages, from birth to 24 mo, KiBS, 2003&#x02013;2009. Data are infant
ages (in days or months), cumulative events (counts), and
Kaplan-Meier estimates of various rates (&#x00025;) with 95&#x00025;
CIs.</p></fn></table-wrap-foot></table-wrap><p>Over the 2-y period from birth to 24 mo, the log-rank test shows a significant
difference in overall HIV transmission when stratified by maternal baseline
viral load categories (&#x0003c;10,000, &#x02265;10,000 copies/ml,
[<italic>p</italic>&#x0200a;=&#x0200a;0.03]), but no
significant differences in the overall HIV-transmission rates when stratified by
study period (<italic>p</italic>&#x0200a;=&#x0200a;0.53), maternal baseline
CD4 count categories (&#x0003c;500 cells/mm<sup>3</sup>, &#x02265;500
cells/mm<sup>3</sup>,
[<italic>p</italic>&#x0200a;=&#x0200a;0.10]), and infant sex
(<italic>p</italic>&#x0200a;=&#x0200a;0.19), and by initial drug
regimen among mothers with baseline CD4 count &#x02265;250 cells/mm<sup>3</sup>
(<italic>p</italic>&#x0200a;=&#x0200a;0.96), although for many of these
variables the magnitude of difference increases gradually over the follow-up
period (<xref ref-type="table" rid="pmed-1001015-t004">Table 4</xref>). Focusing
specifically on differences at 24 mo, HIV-transmission rates were 4.3 percentage
points (&#x02212;0.1 to 5.7 percentage points) higher among infants whose mothers
had baseline CD4 counts &#x0003c;500 cells/mm<sup>3</sup> than those who had baseline
CD4 counts &#x02265;500 cells/mm<sup>3</sup>
(<italic>p</italic>&#x0200a;=&#x0200a;0.06). No difference was detected in
24-mo HIV-transmission rates when using a CD4 cutpoint of 350
cells/mm<sup>3</sup> (<italic>p</italic>&#x0200a;=&#x0200a;0.30).
Likewise, at 24 mo, HIV-transmission rates were 5.7 percentage points
(0.3&#x02013;9.4 percentage points) higher among infants whose mothers had
baseline viral loads &#x02265;10,000 copies/ml than those who had baseline viral
loads &#x0003c;10,000 copies/ml (<italic>p</italic>&#x0200a;=&#x0200a;0.01).</p><table-wrap id="pmed-1001015-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001015.t004</object-id><label>Table 4</label><caption><title>Stratified Kaplan-Meier estimates of HIV-transmission rates among
live-born singletons and first-born infants.</title></caption><alternatives><graphic id="pmed-1001015-t004-4" xlink:href="pmed.1001015.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Stratification Variable</td><td align="left" rowspan="1" colspan="1">Category</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic> at Risk</td><td colspan="5" align="left" rowspan="1">HIV-Transmission Rates (&#x00025;)
(95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">Log-Rank <italic>p</italic>-Value</td><td align="left" rowspan="1" colspan="1">Difference at 24-mo <italic>p</italic>-Value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Birth</td><td align="left" rowspan="1" colspan="1">6 mo</td><td align="left" rowspan="1" colspan="1">12 mo</td><td align="left" rowspan="1" colspan="1">18 mo</td><td align="left" rowspan="1" colspan="1">24 mo</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Enrollment</td><td align="left" rowspan="1" colspan="1">July 2003&#x02013;Jan 2005</td><td align="left" rowspan="1" colspan="1">233</td><td align="left" rowspan="1" colspan="1">2.1 (0.9&#x02013;5.1)</td><td align="left" rowspan="1" colspan="1">5.8 (3.4&#x02013;9.7)</td><td align="left" rowspan="1" colspan="1">6.7 (4.1&#x02013;10.9)</td><td align="left" rowspan="1" colspan="1">7.8 (4.9&#x02013;12.2)</td><td align="left" rowspan="1" colspan="1">7.8 (4.9&#x02013;12.2)</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">July 2005&#x02013;Nov 2006</td><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1">2.8 (1.3&#x02013;5.7)</td><td align="left" rowspan="1" colspan="1">4.4 (2.5&#x02013;7.8)</td><td align="left" rowspan="1" colspan="1">4.8 (2.8&#x02013;8.4)</td><td align="left" rowspan="1" colspan="1">5.8 (3.5&#x02013;9.6)</td><td align="left" rowspan="1" colspan="1">6.3 (3.8&#x02013;10.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Maternal</td><td align="left" rowspan="1" colspan="1">&#x0003c;350</td><td align="left" rowspan="1" colspan="1">193</td><td align="left" rowspan="1" colspan="1">4.7 (2.5&#x02013;8.8)</td><td align="left" rowspan="1" colspan="1">7.4 (4.4&#x02013;12.1)</td><td align="left" rowspan="1" colspan="1">8.0 (4.9&#x02013;12.8)</td><td align="left" rowspan="1" colspan="1">8.6 (5.3&#x02013;13.6)</td><td align="left" rowspan="1" colspan="1">8.6 (5.3&#x02013;13.6)</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">350&#x02013;499</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">0.7 (0.1&#x02013;5.1)</td><td align="left" rowspan="1" colspan="1">3.8 (1.6&#x02013;9.0)</td><td align="left" rowspan="1" colspan="1">5.5 (2.7&#x02013;11.2)</td><td align="left" rowspan="1" colspan="1">7.2 (3.8&#x02013;13.4)</td><td align="left" rowspan="1" colspan="1">8.1 (4.4&#x02013;14.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 count</td><td align="left" rowspan="1" colspan="1">&#x02265;500</td><td align="left" rowspan="1" colspan="1">157</td><td align="left" rowspan="1" colspan="1">1.3 (0.3&#x02013;5.0)</td><td align="left" rowspan="1" colspan="1">3.3 (1.4&#x02013;7.7)</td><td align="left" rowspan="1" colspan="1">3.3 (1.4&#x02013;7.7)</td><td align="left" rowspan="1" colspan="1">4.1 (1.8&#x02013;8.8)</td><td align="left" rowspan="1" colspan="1">4.1 (1.8&#x02013;8.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">(Cells/mm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;500</bold>
</td><td align="left" rowspan="1" colspan="1">330</td><td align="left" rowspan="1" colspan="1">3.0 (1.6&#x02013;5.6)</td><td align="left" rowspan="1" colspan="1">5.9 (3.8&#x02013;9.1)</td><td align="left" rowspan="1" colspan="1">6.9 (4.6&#x02013;10.3)</td><td align="left" rowspan="1" colspan="1">8.0 (5.5&#x02013;11.6)</td><td align="left" rowspan="1" colspan="1">8.4 (5.8&#x02013;12.0)</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&#x02265;500</bold>
</td><td align="left" rowspan="1" colspan="1">157</td><td align="left" rowspan="1" colspan="1">1.3 (0.3&#x02013;5.0)</td><td align="left" rowspan="1" colspan="1">3.3 (1.4&#x02013;7.7)</td><td align="left" rowspan="1" colspan="1">3.3 (1.4&#x02013;7.7)</td><td align="left" rowspan="1" colspan="1">4.1 (1.8&#x02013;8.8)</td><td align="left" rowspan="1" colspan="1">4.1 (1.8&#x02013;8.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Maternal</td><td align="left" rowspan="1" colspan="1">&#x0003c;400</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">3.7 (0.5&#x02013;23.5)</td><td align="left" rowspan="1" colspan="1">3.7 (0.5&#x02013;23.5)</td><td align="left" rowspan="1" colspan="1">3.7 (0.5&#x02013;23.5)</td><td align="left" rowspan="1" colspan="1">3.7 (0.5&#x02013;23.5)</td><td align="left" rowspan="1" colspan="1">3.7 (0.5&#x02013;23.5)</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">400&#x02013;9,999</td><td align="left" rowspan="1" colspan="1">112</td><td align="left" rowspan="1" colspan="1">0.9 (0.1&#x02013;6.2)</td><td align="left" rowspan="1" colspan="1">1.9 (0.5&#x02013;7.2)</td><td align="left" rowspan="1" colspan="1">2.8 (0.9&#x02013;8.5)</td><td align="left" rowspan="1" colspan="1">2.8 (0.9&#x02013;8.5)</td><td align="left" rowspan="1" colspan="1">2.8 (0.9&#x02013;8.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Viral load</td><td align="left" rowspan="1" colspan="1">10,000&#x02013;49,999</td><td align="left" rowspan="1" colspan="1">140</td><td align="left" rowspan="1" colspan="1">3.6 (1.5&#x02013;8.4)</td><td align="left" rowspan="1" colspan="1">5.8 (2.9&#x02013;11.3)</td><td align="left" rowspan="1" colspan="1">6.6 (3.5&#x02013;12.3)</td><td align="left" rowspan="1" colspan="1">8.3 (4.7&#x02013;14.6)</td><td align="left" rowspan="1" colspan="1">8.3 (4.7&#x02013;14.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">(Copies/ml)</td><td align="left" rowspan="1" colspan="1">&#x02265;50,000</td><td align="left" rowspan="1" colspan="1">206</td><td align="left" rowspan="1" colspan="1">2.4 (1.0&#x02013;5.7)</td><td align="left" rowspan="1" colspan="1">6.5 (3.8&#x02013;11.0)</td><td align="left" rowspan="1" colspan="1">7.1 (4.3&#x02013;11.7)</td><td align="left" rowspan="1" colspan="1">8.3 (5.2&#x02013;13.2)</td><td align="left" rowspan="1" colspan="1">8.9 (5.6&#x02013;14.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;10,000</bold>
</td><td align="left" rowspan="1" colspan="1">139</td><td align="left" rowspan="1" colspan="1">1.4 (0.4&#x02013;5.6)</td><td align="left" rowspan="1" colspan="1">2.2 (0.7&#x02013;6.7)</td><td align="left" rowspan="1" colspan="1">3.0 (1.1&#x02013;7.8)</td><td align="left" rowspan="1" colspan="1">3.0 (1.1&#x02013;7.8)</td><td align="left" rowspan="1" colspan="1">3.0 (1.1&#x02013;7.8)</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&#x02265;10,000</bold>
</td><td align="left" rowspan="1" colspan="1">346</td><td align="left" rowspan="1" colspan="1">2.9 (1.6&#x02013;5.3)</td><td align="left" rowspan="1" colspan="1">6.2 (4.1&#x02013;9.4)</td><td align="left" rowspan="1" colspan="1">6.9 (4.6&#x02013;10.2)</td><td align="left" rowspan="1" colspan="1">8.3 (5.8&#x02013;11.9)</td><td align="left" rowspan="1" colspan="1">8.7 (6.1&#x02013;12.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Infant sex</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">223</td><td align="left" rowspan="1" colspan="1">3.1 (1.5&#x02013;6.5)</td><td align="left" rowspan="1" colspan="1">6.5 (3.9&#x02013;10.7)</td><td align="left" rowspan="1" colspan="1">7.6 (4.7&#x02013;12.1)</td><td align="left" rowspan="1" colspan="1">8.7 (5.5&#x02013;13.4)</td><td align="left" rowspan="1" colspan="1">8.7 (5.5&#x02013;13.4)</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">264</td><td align="left" rowspan="1" colspan="1">1.9 (0.8&#x02013;4.5)</td><td align="left" rowspan="1" colspan="1">3.8 (2.1&#x02013;7.0)</td><td align="left" rowspan="1" colspan="1">4.3 (2.4&#x02013;7.6)</td><td align="left" rowspan="1" colspan="1">5.1 (3.0&#x02013;8.7)</td><td align="left" rowspan="1" colspan="1">5.6 (3.4&#x02013;9.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial regimen</td><td align="left" rowspan="1" colspan="1">NVP-based</td><td align="left" rowspan="1" colspan="1">177</td><td align="left" rowspan="1" colspan="1">1.1 (0.3&#x02013;4.4)</td><td align="left" rowspan="1" colspan="1">5.2 (2.8&#x02013;9.8)</td><td align="left" rowspan="1" colspan="1">5.9 (3.2&#x02013;10.6)</td><td align="left" rowspan="1" colspan="1">7.2 (4.2&#x02013;12.4)</td><td align="left" rowspan="1" colspan="1">7.2 (4.2&#x02013;12.4)</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">(CD4&#x02265;250)</td><td align="left" rowspan="1" colspan="1">NFV-based</td><td align="left" rowspan="1" colspan="1">196</td><td align="left" rowspan="1" colspan="1">3.1 (1.4&#x02013;6.7)</td><td align="left" rowspan="1" colspan="1">4.7 (2.5&#x02013;8.8)</td><td align="left" rowspan="1" colspan="1">5.3 (2.9&#x02013;9.6)</td><td align="left" rowspan="1" colspan="1">6.5 (3.7&#x02013;11.2)</td><td align="left" rowspan="1" colspan="1">7.1 (4.2&#x02013;12.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><label/><p>Data are numbers of singleton or first-born (in a multiple birth)
infants initially at risk in each stratification category,
Kaplan-Meier estimates of HIV-transmission rates (&#x00025;) with
95&#x00025; CIs at selected time points, <italic>p</italic>-values
for the log-rank test, and, for stratification variables with two
levels, two-sided <italic>p</italic>-values for the test of
difference at 24 mo.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Maternal Adverse Events</title><p>Of the 522 enrolled women, 66 (12.6&#x00025;) had at least one ARV substituted
between enrollment and 9 mo post partum (<xref ref-type="table" rid="pmed-1001015-t005">Table 5</xref>), including 42 of 310 (13.5&#x00025;)
women initially given NVP and 26 of 522 (5.0&#x00025;) women initially given ZDV.
Of these 66 women, 53 (80&#x00025;) had an ARV-related SAE, and 13 (20&#x00025;)
had an illness that required treatment incompatible with NVP (e.g., rifampicin
for tuberculosis, warfarin for anticoagulation). One participant had NFV
substituted due to neutropenia. Most SAEs were due to common causes of morbidity
in this region and HIV-related opportunistic infections (e.g., malaria,
tuberculosis). SAEs most likely associated with study ARVs included anemia,
neutropenia, hepatotoxicity, and rash. Grade 3 or 4 anemia (Hb&#x0003c;7.0 g/dl) and
neutropenia (neutrophil count &#x0003c;750 cells/ml measured on two or more
consecutive visits), occurred among 31 and 36 participants, respectively, and
nine participants had both. The Hb concentration among most participants
increased over time: Hb&#x02264;10.0 g/dl for 58&#x00025; at baseline and 9&#x00025; at
9 mo post partum. In most cases the neutropenia resolved without substitution of
ARVs. Overall, 22 of 522 (4.2&#x00025;) participants required ARV substitution
because of anemia and/or neutropenia (<xref ref-type="table" rid="pmed-1001015-t005">Table 5</xref>). Hepatotoxicity (&#x02265;grade 2) SAEs
occurred among 33 participants. Of the 14 with grade 3 or 4 hepatotoxicity, 12
were participants taking NVP. Among participants who initially received NVP,
grade 3 or 4 hepatotoxicity occurred in 9 of 196 (5&#x00025;) women with a
baseline CD4 count of &#x02265;250 cells/mm<sup>3</sup> versus three of 114
(3&#x00025;) women with CD4 count of &#x0003c;250 cells/mm<sup>3</sup>
(RR&#x0200a;=&#x0200a;1.7, 95&#x00025; CI 0.5&#x02013;6.3). There were 16 rash
SAEs, six with concomitant hepatotoxicity; all occurred among women on NVP. Rash
SAEs occurred in 12 of 196 (6&#x00025;) women with a baseline CD4 count of
&#x02265;250 cells/mm<sup>3</sup> (including three cases of Stevens-Johnson Syndrome,
all with CD4 counts of &#x0003e;350 cells/mm<sup>3</sup>) versus four of 114
(4&#x00025;) women with CD4 counts of &#x0003c;250 cells/mm<sup>3</sup>
(RR&#x0200a;=&#x0200a;1.7, 95&#x00025; CI 0.6&#x02013;5.3). All rash SAEs
resolved after cessation of NVP. Of 12 maternal deaths (five before 9 mo), nine
were attributed to opportunistic infections and three to progression of
preexisting cardiac disease. No deaths were attributed to ARVs.</p><table-wrap id="pmed-1001015-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001015.t005</object-id><label>Table 5</label><caption><title>Maternal SAEs during intervention period (enrollment to 9 mo post
partum), number resulting in ARV substitution, and proportion of women
initiated on ARV who required substitution.</title></caption><alternatives><graphic id="pmed-1001015-t005-5" xlink:href="pmed.1001015.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Serious Adverse Event</td><td align="left" rowspan="1" colspan="1">Total <italic>n</italic> Women with SAE
(<italic>n</italic>&#x0200a;=&#x0200a;522)</td><td align="left" rowspan="1" colspan="1">Number of Women Requiring an ARV Substitution for
Each SAE/Illness<xref ref-type="table-fn" rid="nt107">a</xref>
</td><td colspan="3" align="left" rowspan="1">Number of Maternal ARV Substituted
(&#x00025;)</td></tr><tr><td colspan="2" align="left" rowspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NVP
(<italic>n</italic>&#x0200a;=&#x0200a;310)</td><td align="left" rowspan="1" colspan="1">ZDV
(<italic>n</italic>&#x0200a;=&#x0200a;522)</td><td align="left" rowspan="1" colspan="1">NFV
(<italic>n</italic>&#x0200a;=&#x0200a;212)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Potentially ARV-related</bold>
</td><td align="left" rowspan="1" colspan="1">Neutropenia</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4 (0.8&#x00025;)</td><td align="left" rowspan="1" colspan="1">1 (0.5&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Anemia</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">14 (2.7&#x00025;)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Anemia and neutropenia</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3 (0.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hepatotoxicity<xref ref-type="table-fn" rid="nt108">b</xref>
</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">15 (4.8&#x00025;)</td><td align="left" rowspan="1" colspan="1">2 (0.4&#x00025;)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rash</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">8 (2.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hepatotoxicity and rash<xref ref-type="table-fn" rid="nt109">c</xref>
</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">6 (1.9&#x00025;)</td><td align="left" rowspan="1" colspan="1">2 (0.4&#x00025;)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Illness requiring ARV change</bold>
</td><td align="left" rowspan="1" colspan="1">TB treatment<xref ref-type="table-fn" rid="nt110">d</xref>
</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">10 (3.2&#x00025;)</td><td align="left" rowspan="1" colspan="1">1 (0.2&#x00025;)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DVT treatment</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2 (0.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hyperbilirubinemia</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1 (0.3&#x00025;)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Other SAEs</bold>
</td><td align="left" rowspan="1" colspan="1">Malaria</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pneumonia</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Death</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Gastroenteritis</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">194</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">42 (13.5&#x00025;)</td><td align="left" rowspan="1" colspan="1">26 (5&#x00025;)</td><td align="left" rowspan="1" colspan="1">1 (0.5&#x00025;)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt107"><label>a</label><p>Each participant only reported once for primary reason for ARV
substitution between enrollment and 9-mo post partum.</p></fn><fn id="nt108"><label>b</label><p>Includes one participant where SAE attributed to ZDV, but stopped all
ARVs.</p></fn><fn id="nt109"><label>c</label><p>Includes two participants who stopped both NVP and ZDV.</p></fn><fn id="nt110"><label>d</label><p>Includes one participant who stopped both NVP and ZDV.</p></fn><fn id="nt111"><label/><p>DVT, deep venous thrombosis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Infant Adverse Events</title><p>The most common causes of child SAEs included diarrhea, malaria, pneumonia, and
anemia. Of the 146 reported diarrhea SAEs, 86 (59&#x00025;) occurred between the
5- and 9-mo study visits (peri-weaning period). By 24-mo 49 (10&#x00025;) of
first-born children had died (two additional deaths occurred among second-born
children); 42 (86&#x00025;) deaths occurred during the first year of life. The
three most frequent causes of death were diarrhea (35&#x00025;), pneumonia
(16&#x00025;), and respiratory failure (12&#x00025;). Twelve deaths due to
diarrhea occurred during the peri-weaning period and thus could be attributed to
early weaning; two of these infants were HIV positive. No child deaths or other
SAEs were clearly attributable to maternal or child ARVs.</p></sec><sec id="s3d"><title>Adherence to Regimen</title><p>Of the 522 enrolled participants, 439 (84&#x00025;) took triple-ARV prophylaxis
through 6 mo post partum, whereas 83 (16&#x00025;) stopped prematurely due to
withdrawal (56&#x00025;), infant death/stillbirth (19&#x00025;), breastfeeding
cessation (7&#x00025;), maternal death (5&#x00025;), noncompliance with
drugs/study visits (5&#x00025;), and other reasons (7&#x00025;). Among
participants on study at 6 mo, 82&#x00025; (359/439) were &#x02265;95&#x00025; adherent
to the study ARVs. Of those participants with viral load testing results,
5&#x00025; (27/520) at enrollment, 67&#x00025; (333/497) at delivery, and
80&#x00025; (348/435) at 6 mo post partum had an undetectable viral load (defined
as &#x0003c;400 RNA copies/ml). Among the 333 participants with an undetectable viral
load at delivery, 88&#x00025; (263/298) at 14 wk and 89&#x00025; (258/294) at 6 mo
post partum (79&#x00025; [227/288] at both times) had an undetectable
viral load.</p><p>Among live-born infants, 98&#x00025; (494/502) received a single dose of NVP at
delivery. Mixed feeding before 5 mo was documented for 22&#x00025; (109/502) of
live-born infants. The triplets were never breastfed but were provided formula.
Of the HIV-negative infants on study at 6 mo, 87&#x00025; (379/434) reportedly
had stopped breastfeeding by 6 mo, in accordance with study recommendations.
Nine infants who tested HIV negative at 6 mo subsequently became HIV infected;
none of their mothers, who had been advised to stop breastfeeding, were
currently receiving ARVs. When probed about possible causes of infection only
two of these mothers acknowledged breastfeeding their infants beyond 6 mo.</p></sec></sec><sec id="s4"><title>Discussion</title><sec id="s4a"><title>Transmission Rates and Comparison to Other Trials</title><p>The KiBS achieved 6-wk and 18-mo HIV-transmission rates of 4.2&#x00025; and
6.7&#x00025;, respectively. These rates are less than half the corresponding
HIV-transmission rates of 11.8&#x00025; and 15.7&#x00025; observed in the HIVNET
012 study <xref rid="pmed.1001015-Jackson1" ref-type="bibr">[8]</xref>
conducted in Uganda, using single-dose maternal and infant NVP. Likewise, KiBS
achieved a 4-mo transmission rate of 4.6&#x00025;, a 77&#x00025; reduction
compared with the corresponding rate of 19.9&#x00025; reported in a study of the
impact of maternal malaria on perinatal HIV transmission <xref rid="pmed.1001015-Ayisi1" ref-type="bibr">[19]</xref>, conducted in Kisumu between
1996 and 2001 without a PMTCT intervention. Several studies have reported
comparable 6-mo HIV-transmission rates to that of KiBS (5.0&#x00025;
[3.4&#x00025;&#x02013;7.4&#x00025;]). MITRA Plus <xref rid="pmed.1001015-Kilewo1" ref-type="bibr">[20]</xref> in Tanzania, which provided
maternal ZDV, 3TC, and either NVP or NFV during late pregnancy through 6 mo of
breastfeeding (infants received ZDV&#x0002b;3TC for 1 wk after birth), reported a
6-mo transmission rate of 5.0&#x00025; (3.2&#x00025;&#x02013;7.0&#x00025;). Two
recently completed randomized trials also reported similar transmission rates in
the arms comparable to KiBS. In one arm of the BAN study in Malawi <xref rid="pmed.1001015-Chasela1" ref-type="bibr">[21]</xref>,
breastfeeding mothers with CD4 counts &#x02265;250 cells/mm<sup>3</sup> and their
infants received a short-course regimen including single-dose NVP at birth and
ZDV and 3TC for 7 d and then mothers received a maternal triple-ARV regimen
(Combivir and either NVP or a protease inhibitor) for 28 wk. At 28 wk post
partum the transmission rate among all infants randomized to this arm was
8.2&#x00025; (6.5&#x00025;&#x02013;10.3&#x00025;). The Kesho Bora study <xref rid="pmed.1001015-deVincenzi1" ref-type="bibr">[22]</xref>
randomized women at 28&#x02013;36 wk gestation, with CD4 counts 200&#x02013;500
cells/mm<sup>3</sup> to either a triple-ARV regimen
(ZDV&#x0002b;3TC&#x0002b;Lopinavir/ritonavir [Kaletra, Abbott]) or a short
ARV regimen (ZDV through delivery plus single-dose NVP in labor). The 6-mo
transmission rate in the triple-ARV arm was 4.9&#x00025;
(3.1&#x00025;&#x02013;7.5&#x00025;). Two other studies using triple-ARV regimens
have shown somewhat lower rates. The AMATA study in Rwanda <xref rid="pmed.1001015-Peltier1" ref-type="bibr">[23]</xref>, which provided maternal
triple ARVs from 28 wk gestation and for up to 6 mo of breastfeeding, reported a
9-mo transmission rate of 1.8&#x00025; (0.7&#x00025;&#x02013;4.8&#x00025;). The Mma
Bana study in Botswana <xref rid="pmed.1001015-Shapiro1" ref-type="bibr">[24]</xref>, which provided maternal triple ARVs from 28 to 34 wk
gestation through 6 mo of breastfeeding, reported a 6-mo transmission rate of
1.1&#x00025; (0.5&#x00025;&#x02013;2.2&#x00025;).</p><p>In KiBS, 62.5&#x00025; of the infant infections occurred by 42 d, i.e., primarily
in utero or intrapartum. The median duration on ARVs antepartum was 5.6 wk and
33&#x00025; of tested participants had not achieved undetectable viral load at
delivery. The duration on ARVs antepartum may explain some of the differences in
transmission rates seen in the PMTCT studies mentioned earlier. The Mma Bana
<xref rid="pmed.1001015-Shapiro1" ref-type="bibr">[24]</xref> and
the AMATA study <xref rid="pmed.1001015-Peltier1" ref-type="bibr">[23]</xref> reported median duration on ARVs antepartum of 11 wk
and 16.4 wk, respectively, and both had 6-wk transmission rates &#x02264;1.3&#x00025;.
Mitra Plus <xref rid="pmed.1001015-Kilewo1" ref-type="bibr">[20]</xref> reported a median duration on ARVs antepartum of 5.4
wk and a 6-wk transmission rate of 4.1&#x00025;, very similar to KiBS
(4.2&#x00025;). Kesho Bora <xref rid="pmed.1001015-deVincenzi1" ref-type="bibr">[22]</xref> reported 42.6&#x00025; of the participants receiving
&#x0003c;6 wk of triple ARVs antepartum and a transmission rate of 3.3&#x00025;. Given
these findings and the transmission rates below 2&#x00025; in countries where
triple-ARV prophylaxis is initiated during the second trimester and where
breastfeeding is avoided <xref rid="pmed.1001015-Burr1" ref-type="bibr">[25]</xref>, it is likely that initiating ARVs earlier during
pregnancy in this study would have further reduced in utero and intrapartum
transmission However, timely initiation of ARVs may be a challenge in areas
where many women present late for antenatal care. A 2002 study of recently
delivered women in rural western Kenya showed that 64&#x00025; first visited the
antenatal clinic in the third trimester <xref rid="pmed.1001015-vanEijk1" ref-type="bibr">[26]</xref>.</p><p>The cumulative transmission between 6 wk and 24 mo, probably attributable to
breastfeeding, was 3.2&#x00025; (95&#x00025; CI 1.9&#x00025;&#x02013;5.5&#x00025;).
Nine infants became infected after 6 mo post partum. We probed the mothers for
possible mechanisms of late infection; seven of them denied any breastfeeding
beyond 6 mo, two infants underwent a traditional scarring procedure, and no
mothers reported premastication of food or breastfeeding by other women (neither
of these practices was common among KiBS participants). Thus, unreported
continued breastfeeding remains the most likely mechanism of late infection.
Cessation of breastfeeding may have been difficult because of insufficient
resources, fear of stigma and unintentional disclosure, and the tradition of
breastfeeding well beyond 6 mo. Family support and cultural norms, which are
important to a mother's decision about when to stop breastfeeding, should
be considered when promoting early cessation of breastfeeding <xref rid="pmed.1001015-Morgan1" ref-type="bibr">[27]</xref>. Rapid
weaning may also have contributed to infant HIV infection because of its
association with elevations in breast milk HIV levels and mastitis, as observed
in the Zambia Exclusive Breastfeeding Study <xref rid="pmed.1001015-Kuhn1" ref-type="bibr">[28]</xref>. The revised WHO treatment
criteria recommend treatment for those with CD4 counts &#x0003c;350
cells/mm<sup>3</sup> or WHO stage 3 or 4. Whereas we observed lower 24-mo
HIV-transmission rates among infants whose mothers had higher CD4 count levels
(&#x02265;500 cells/mm<sup>3</sup>), we did not find any differences in infant
transmission rates for those with maternal baseline CD4 counts between
350&#x02013;499 cells/mm<sup>3</sup> and those with CD4 counts &#x0003c;350
cells/mm<sup>3</sup>.</p><p>The rates of infant HIV transmission or death at 6, 12, and 18 mo in KIBS were
8.5&#x00025; (6.3&#x00025;&#x02013;11.4&#x00025;), 13.5&#x00025;
(10.7&#x00025;&#x02013;16.9&#x00025;), and 15.3&#x00025;
(12.3&#x00025;&#x02013;18.9&#x00025;), respectively. These rates are similar to
those reported at the same time points in MITRA Plus <xref rid="pmed.1001015-Kilewo1" ref-type="bibr">[20]</xref>, namely 8.6&#x00025;
(6.0&#x00025;&#x02013;11.2&#x00025;), 12.8&#x00025; (9.6&#x00025;&#x02013;16.0&#x00025;),
and 13.6&#x00025; (10.3&#x00025;&#x02013;16.9&#x00025;). By comparison, the rate of
HIV transmission or death at 18 mo in HIVNET 012 <xref rid="pmed.1001015-Jackson1" ref-type="bibr">[8]</xref> was 20.7&#x00025;
(16.2&#x00025;&#x02013;23.8&#x00025;). Although the study met the objective of a
50&#x00025; reduction in transmission compared to HIVNET 012 historic data, a
corresponding reduction in the combined endpoint of transmission or death was
not achieved. The failure to achieve this latter reduction may reflect
differences in study location, population, and access to medical care among
other possible factors.</p></sec><sec id="s4b"><title>Adherence and Adverse Events</title><p>The KiBS study intervention appeared well tolerated and safe. Most (84&#x00025;)
of those enrolled took ARVs until 6 mo post partum, even though most did not
meet treatment criteria for themselves. The implications of initiating triple
ARVs when not needed for their own health and then stopping ARVs after several
months require further study. Women who participated in this trial are currently
being enrolled into a study to evaluate their subsequent response to ARV
treatment. The development of ARV resistance among infants is reported elsewhere
in this issue <xref rid="pmed.1001015-Zeh1" ref-type="bibr">[29]</xref>. Of those who completed the intervention, 82&#x00025;
were &#x02265;95&#x00025; adherent. Furthermore, an evaluation of viral load levels
demonstrated that for most women whose viral load was suppressed at delivery,
suppression was maintained at 6 mo post partum. There were no unexpected
ARV-related SAEs, although infant gastroenteritis SAEs increased during the
weaning period. The rates of NVP- and ZDV-related SAEs were generally consistent
with those reported in the prescribing information from the drug manufacturers
<xref rid="pmed.1001015-Boehringer2" ref-type="bibr">[17]</xref>,<xref rid="pmed.1001015-GlaxoSmithKline1" ref-type="bibr">[18]</xref>, although we did
not find a significant increase in NVP-related hepatotoxicity and rash among
mothers with CD4 counts above 250 cells/mm<sup>3</sup> as had been reported in
nonpregnant women in other trials. Our findings are consistent with findings
from a recent analysis of HIV-infected pregnant women on ARVs <xref rid="pmed.1001015-Ouyang1" ref-type="bibr">[30]</xref> in the US
where a significant differential by CD4 count was likewise not evident. Observed
neutropenia was attributed primarily to lower normal physiologic levels for
African women <xref rid="pmed.1001015-Brooks1" ref-type="bibr">[31]</xref>; the use of US-based toxicity tables may have
resulted in overestimation of neutropenia-related SAEs.</p></sec><sec id="s4c"><title>Advantages</title><p>One advantage of this study was the use of a simple regimen that did not require
different drugs at different time points in the pregnancy-delivery-breastfeeding
continuum, and which could be provided to all HIV-infected women regardless of
CD4 count. In many resource-limited settings one may not have the time to wait
for a CD4 count before deciding what regimen to start for PMTCT. While the study
regimen was changed in response to concerns about NVP toxicity, our subsequent
analysis shows that women with higher CD4 counts on NVP treatment are not at
increased risk compared to women with lower CD4 counts.</p></sec><sec id="s4d"><title>Limitations</title><p>A limitation of this study is the lack of a concurrent control group. This
decision was based on cost constraints and anticipated difficulty in enrolling
adequate numbers for a randomized trial. Another limitation impacting the
generalizability of this study includes the intensity of visits, particularly
during the intervention period. The Kenya Ministry of Health currently schedules
vaccinations and vitamin A dosing in children &#x02264;2 y of age at birth, 6, 10,
and 14 wk, and 6, 9, 12, 18, and 24 mo <xref rid="pmed.1001015-Ministry1" ref-type="bibr">[32]</xref>. The study visit schedule
was initially designed to follow the vaccination schedule with only two
additional visits at 2 wk and 15 mo. We modified the protocol in 2005, adding
visits at 5, 7, and 8 mo because of concerns about the increased incidence of
diarrhea during the peri-weaning period. These visits focused on infant feeding,
weight, and health. No testing for HIV was done at the 10-wk, and 5-, 7-, and
8-mo visits. Other limitations include the difficulty in accurately assessing
gestational age, the predominantly urban population, participant self-selection
bias, and possibility that some participants may have given socially desirable
responses to questions about adherence to ARVs or infant feeding recommendations
because of the strong emphasis on these issues by study staff.</p></sec><sec id="s4e"><title>Summary</title><p>The KiBS demonstrates the feasibility and safety of the use of triple-ARV
prophylaxis from 34&#x02013;36 wk gestation through 6 mo of breastfeeding for
PMTCT and achieved low transmission rates among HIV-positive women who choose to
breastfeed in Kisumu, Kenya, a resource-limited setting. This study reinforces
the findings of other similar trials. The study findings were presented at the
WHO expert consultation on new and emerging evidence on the use of ARV drugs for
PMTCT in November 2008 <xref rid="pmed.1001015-WHO4" ref-type="bibr">[33]</xref> and have added to the body of evidence supporting the
recent WHO guidelines <xref rid="pmed.1001015-WHO5" ref-type="bibr">[34]</xref>, which recommend either the mother receiving triple
ARVs or the infant receiving ARV prophylaxis. Further studies are still needed
to determine the most appropriate strategies and optimal length of
breastfeeding; these questions are being considered in the large PROMISE study
(NIH/IMPAACT) <xref rid="pmed.1001015-Fowler1" ref-type="bibr">[35]</xref>. Promoting HIV testing among pregnant women and
expectant fathers and ensuring that those who test positive receive effective
and timely PMTCT services and treatment remains a critical worldwide challenge;
however, the demonstration of effective interventions now provide greater
leverage for women to test and enroll into PMTCT programs. In addition, the
greater availability of ARVs, especially combination pills that simplify
regimens, vastly improves the prospects for widespread implementation of triple
ARVs during pregnancy and breastfeeding for PMTCT in sub-Saharan Africa, the
heart of the current AIDS pandemic.</p></sec></sec><sec sec-type="supplementary-material" id="s6"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pmed.1001015.s001"><label>Text S1</label><caption><p>Protocol.</p><p>(PDF)</p></caption><media xlink:href="pmed.1001015.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pmed.1001015.s002"><label>Text S2</label><caption><p>CONSORT Checklist.</p><p>(DOC)</p></caption><media xlink:href="pmed.1001015.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors are grateful to: KiBS participating mothers and infants; KiBS staff for
their diligent work in the field; GlaxoSmithKline for donation of Combivir;
Boehringer Ingelheim for donation of Viramune; staff of New Nyanza Provincial
General Hospital and Kisumu District Hospital for their assistance in recruitment
and for caring for study participants; KEMRI/CDC Kisumu Community Advisory Board for
their patience and interest in the study; Marie S. Morgan, ELS, writer-editor at
CDC, for assistance with editing this paper.</p><p>
<bold>KiBS Study Team</bold> (Kisumu, Kenya and Atlanta, Georgia, United States)</p><p>Study coordinators: A. Kombo, R. Masaba.</p><p>Physician: D. Mwakangalu.</p><p>Clinical officers: F. Angira, R. Lando, M. Owino.</p><p>Nurses: K. Achola, G. Muga, J. Naulikha, I. Nyan'gau, L. Ochieng, I. Ouma.</p><p>Pharmacist: V. Mudhune.</p><p>Pharmacy technician: P. Odhiambo.</p><p>Nutritionists: M. Nyagaya, J. Okanda.</p><p>Medical records: A. Rangang', V. Sewe, E. Ayuo, G. Mwenda.</p><p>Home follow-up: H. Gamba, P. Okola, P. On'gwena, R. Opuro, J. Oruko, M. Othanya,
E. Owuonda.</p><p>Administration: J. Adhiambo, C. Amondi, R. Goldstine, M. Mugo, S. Odhiambo, P.
Wamiru, S. Achieng.</p><p>Laboratory technologists: B. Akoth, P. Bondo, E. Mimba, H. Musulumma, D. Mwaengo, L.
Nafisa, B. Nyakira, E. Odawo, N. Odidi, J. Okonji, P. Omollo, F. Omondi, K. Omondi,
J. Osoga, S. Oswago, V. Ouma, B. Owino, B. Oyaro, C. Zeh.</p><p>Counselors: J. Omanga, C. Ouma.</p><p>Peer counselors: J. Odidi, E. Rambara, A. Amollo.</p><p>Behavioral scientists: M. Nyirkuri, K. Ondenge.</p><p>Data team: S. Aremo, F. Motende, J. Muhanji, P. Nasokho, C. Ndila, R. Ndivo, E.
Obade, P. Ogindo, H. Okuku, S. Girde, X. Lu.</p><p>Consultants: A. Bell, K. Brattegard, A. van't Hoog, A. van Eijk, D. Jamieson, B.
Marston, L. Marum, D. Mbori-Ngacha, A. Misore, J. Mwidau, J. Odondi, C. Oyoo, M.
Oziemkowska, Y. Ping Shi, D. Rosen, D. Taren, J. Vulule, P. Peters, P. Weidle, J.
Brooks, S. Nesheim, A. Taylor, S. Danner.</p></ack><fn-group><fn fn-type="COI-statement"><p>The Academic Editor, Lynne Mofenson, has disclosed that she worked with authors
Mary Glenn Fowler and Michael C. Thigpen on other projects unrelated to the
study reported in this paper. The authors have no competing interests to
declare.</p></fn><fn fn-type="financial-disclosure"><p>Funding for the study was provided by the Kenya Medical Research Institute
(KEMRI) through a cooperative agreement with the US Centers for Disease Control
and Prevention (CDC). Study drugs were provided by GlaxoSmithKline and
Boehringer Ingelheim. The study design, data collection instruments, data
collection, data analysis, decision to publish, and preparation of the
manuscript were led by CDC and KEMRI staff based in Atlanta and at the KEMRI/CDC
Field Station in Kisumu, Kenya. The companies that donated study drugs had an
opportunity to review and comment on the manuscript, but otherwise did not have
any role in the study. The findings and conclusions in this article are those of
the authors and do not necessarily represent the views of the CDC. Use of trade
names is for identification purposes only and does not constitute endorsement by
the CDC or the Department of Health and Human Services. This publication has
been approved by the Director of the Kenya Medical Research Institute.</p></fn></fn-group><ref-list><title>References</title><ref id="pmed.1001015-UNAIDS1"><label>1</label><element-citation publication-type="other">
<collab>UNAIDS</collab>
<year>2010</year>
<article-title>UNAIDS Report on the Global AIDS Epidemic.</article-title>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/globalreport/default.htm">http://www.unaids.org/globalreport/default.htm</ext-link>. Accessed 24
January 2011</comment>
</element-citation></ref><ref id="pmed.1001015-DeCock1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Cock</surname><given-names>KM</given-names></name><name><surname>Fowler</surname><given-names>MG</given-names></name><name><surname>Mercier</surname><given-names>E</given-names></name><name><surname>de Vincenzi</surname><given-names>I</given-names></name><name><surname>Saba</surname><given-names>J</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Prevention of mother-to-child HIV transmission in resource-poor
countries: translating research into policy and practice.</article-title>
<source>JAMA</source>
<volume>283</volume>
<fpage>1175</fpage>
<lpage>1182</lpage>
<pub-id pub-id-type="pmid">10703780</pub-id></element-citation></ref><ref id="pmed.1001015-VandePerre1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van de Perre</surname><given-names>P</given-names></name><name><surname>Simonon</surname><given-names>A</given-names></name><name><surname>Msellati</surname><given-names>P</given-names></name><name><surname>Hitimana</surname><given-names>DG</given-names></name><name><surname>Vaira</surname><given-names>D</given-names></name><etal/></person-group>
<year>1991</year>
<article-title>Postnatal transmission of human immunodeficiency virus type 1
from mother to infant. A prospective cohort study in Kigali,
Rwanda.</article-title>
<source>N Engl J Med</source>
<volume>325</volume>
<fpage>593</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="pmid">1812850</pub-id></element-citation></ref><ref id="pmed.1001015-Kreiss1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kreiss</surname><given-names>J</given-names></name></person-group>
<year>1997</year>
<article-title>Breastfeeding and vertical transmission of HIV-1.</article-title>
<source>Acta Paediatr Suppl</source>
<volume>421</volume>
<fpage>113</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="pmid">9240870</pub-id></element-citation></ref><ref id="pmed.1001015-Bulterys1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bulterys</surname><given-names>M</given-names></name><name><surname>Fowler</surname><given-names>MG</given-names></name><name><surname>Van Rompay</surname><given-names>KK</given-names></name><name><surname>Kourtis</surname><given-names>AP</given-names></name></person-group>
<year>2004</year>
<article-title>Prevention of mother-to-child transmission of HIV-1 through
breast-feeding: past, present, and future.</article-title>
<source>J Infect Dis</source>
<volume>189</volume>
<fpage>2149</fpage>
<lpage>2153</lpage>
<pub-id pub-id-type="pmid">15181560</pub-id></element-citation></ref><ref id="pmed.1001015-The1"><label>6</label><element-citation publication-type="journal">
<collab>The PETRA Study Team</collab>
<year>2002</year>
<article-title>Efficacy of three short-course regimens of zidovudine and
lamivudine in preventing early and late transmission of HIV-1 from mother to
child in Tanzania, South Africa, and Uganda (Petra study): a randomised,
double-blind, placebo-controlled trial.</article-title>
<source>Lancet</source>
<volume>359</volume>
<fpage>1178</fpage>
<lpage>1186</lpage>
<pub-id pub-id-type="pmid">11955535</pub-id></element-citation></ref><ref id="pmed.1001015-Dabis1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dabis</surname><given-names>F</given-names></name><name><surname>Bequet</surname><given-names>L</given-names></name><name><surname>Ekouevi</surname><given-names>DK</given-names></name><name><surname>Viho</surname><given-names>I</given-names></name><name><surname>Rouet</surname><given-names>F</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Field efficacy of zidovudine, lamivudine and single-dose
nevirapine to prevent peripartum HIV transmission.</article-title>
<source>AIDS</source>
<volume>19</volume>
<fpage>309</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="pmid">15718842</pub-id></element-citation></ref><ref id="pmed.1001015-Jackson1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jackson</surname><given-names>JB</given-names></name><name><surname>Musoke</surname><given-names>P</given-names></name><name><surname>Fleming</surname><given-names>T</given-names></name><name><surname>Guay</surname><given-names>LA</given-names></name><name><surname>Bagenda</surname><given-names>D</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Intrapartum and neonatal single-dose nevirapine compared with
zidovudine for prevention of mother-to-child transmission of HIV-1 in
Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised
trial.</article-title>
<source>Lancet</source>
<volume>362</volume>
<fpage>859</fpage>
<lpage>868</lpage>
<pub-id pub-id-type="pmid">13678973</pub-id></element-citation></ref><ref id="pmed.1001015-Leroy1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leroy</surname><given-names>V</given-names></name><name><surname>Ekouevi</surname><given-names>DK</given-names></name><name><surname>Becquet</surname><given-names>R</given-names></name><name><surname>Viho</surname><given-names>I</given-names></name><name><surname>Dequae-Merchadou</surname><given-names>L</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>18-Month effectiveness of short-course antiretroviral regimens
combined with alternatives to breastfeeding to prevent HIV mother-to-child
transmission.</article-title>
<source>PLoS ONE</source>
<volume>3</volume>
<fpage>e1645</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0001645">10.1371/journal.pone.0001645</ext-link></comment>
<pub-id pub-id-type="pmid">18286200</pub-id></element-citation></ref><ref id="pmed.1001015-WHO1"><label>10</label><element-citation publication-type="other">
<collab>WHO, UNICEF, UNAIDS, UNFPA</collab>
<year>1998</year>
<article-title>HIV and infant feeding: a guide for health-care managers and
supervisors.</article-title>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/nutrition/publications/hivaids/9241591234/en/">www.who.int/nutrition/publications/hivaids/9241591234/en/</ext-link>.
Accessed 24 January 2011</comment>
</element-citation></ref><ref id="pmed.1001015-WHO2"><label>11</label><element-citation publication-type="other">
<collab>WHO, UNICEF, UNFPA, UNAIDS</collab>
<year>2006</year>
<comment>HIV and infant feeding: update based on the technical consultation held
on behalf of the Inter-agency Team (IATT) on Prevention of HIV Infections in
Pregnant Women, Mothers and their Infants. 25&#x02013;27 October 2006;
<ext-link ext-link-type="uri" xlink:href="http://whqlibdoc.who.int/publications/2007/9789241595964_eng.pdf">http://whqlibdoc.who.int/publications/2007/9789241595964_eng.pdf</ext-link>.
Accessed 24 January 2011</comment>
</element-citation></ref><ref id="pmed.1001015-Boehringer1"><label>12</label><element-citation publication-type="book">
<collab>Boehringer Ingelheim Pharmaceuticals Inc</collab>
<year>2005</year>
<source>Nevirapine (Viramune) revised label</source>
<publisher-loc>Ridgefield (Connecticut, United States of
America)</publisher-loc>
<publisher-name>Boehringer Ingelheim Pharmaceuticals, Inc</publisher-name>
</element-citation></ref><ref id="pmed.1001015-WHO3"><label>13</label><element-citation publication-type="other">
<collab>WHO</collab>
<year>2003</year>
<article-title>Scaling up antiretroviral therapy in resource-limited settings:
treatment guidelines for a public health approach.</article-title>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf">http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf</ext-link>.
Accessed 24 January 2011</comment>
</element-citation></ref><ref id="pmed.1001015-Rutenberg1"><label>14</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Rutenberg</surname><given-names>N</given-names></name></person-group>
<year>2003</year>
<source>Infant feeding counseling within Kenyan and Zambian PMTCT services: how
well does it promote good feeding practices?</source>
<publisher-loc>Washington (D.C.)</publisher-loc>
<publisher-name>Population Council</publisher-name>
</element-citation></ref><ref id="pmed.1001015-NIH1"><label>15</label><element-citation publication-type="other">
<collab>NIH, NIAID</collab>
<year>1992</year>
<article-title>Division of AIDS table for grading severity of adult adverse
experiences.</article-title>
<comment><ext-link ext-link-type="uri" xlink:href="http://rcc.tech-res.com/Document/safetyandpharmacovigilance/ToxicityTables_Adult_TRP_v01a.pdf.">http://rcc.tech-res.com/Document/safetyandpharmacovigilance/ToxicityTables_Adult_TRP_v01a.pdf.</ext-link>
Accessed 24 January 2011</comment>
</element-citation></ref><ref id="pmed.1001015-NIH2"><label>16</label><element-citation publication-type="other">
<collab>NIH, NIAID</collab>
<year>1994</year>
<article-title>Division of AIDS table for grading severity of pediatric adverse
events.</article-title>
<comment><ext-link ext-link-type="uri" xlink:href="http://rcc.tech-res.com/Document/safetyandpharmacovigilance/ToxicityTables_Pediatric_Over3MonthsAge_v03.pdf">http://rcc.tech-res.com/Document/safetyandpharmacovigilance/ToxicityTables_Pediatric_Over3MonthsAge_v03.pdf</ext-link>
and <ext-link ext-link-type="uri" xlink:href="http://rcc.tech-res.com/Document/safetyandpharmacovigilance/ToxicityTables_Pediatric_Under3MonthsAge_v02.pdf">http://rcc.tech-res.com/Document/safetyandpharmacovigilance/ToxicityTables_Pediatric_Under3MonthsAge_v02.pdf</ext-link>.
Accessed 24 January 2011</comment>
</element-citation></ref><ref id="pmed.1001015-Boehringer2"><label>17</label><element-citation publication-type="book">
<collab>Boehringer Ingelheim Pharmaceuticals Inc</collab>
<year>2008</year>
<source>Prescribing information: VIRAMUNE (nevirapine)</source>
<publisher-loc>Ridgefield (Connecticut, United States of
America)</publisher-loc>
<publisher-name>Boehringer Ingelheim Pharmaceuticals, Inc</publisher-name>
</element-citation></ref><ref id="pmed.1001015-GlaxoSmithKline1"><label>18</label><element-citation publication-type="book">
<collab>GlaxoSmithKline</collab>
<year>2007</year>
<source>Prescribing information: Combivir (lamivudine/zidouvdine)
tablets</source>
<publisher-loc>Research Triangle Park, (North Carolina, United
States)</publisher-loc>
<publisher-name>GlaxoSmithKline</publisher-name>
</element-citation></ref><ref id="pmed.1001015-Ayisi1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ayisi</surname><given-names>JG</given-names></name><name><surname>van Eijk</surname><given-names>AM</given-names></name><name><surname>Newman</surname><given-names>RD</given-names></name><name><surname>ter Kuile</surname><given-names>FO</given-names></name><name><surname>Shi</surname><given-names>YP</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Maternal malaria and perinatal HIV transmission, western
Kenya.</article-title>
<source>Emerg Infect Dis</source>
<volume>10</volume>
<fpage>643</fpage>
<lpage>652</lpage>
<pub-id pub-id-type="pmid">15200854</pub-id></element-citation></ref><ref id="pmed.1001015-Kilewo1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kilewo</surname><given-names>C</given-names></name><name><surname>Karlsson</surname><given-names>K</given-names></name><name><surname>Ngarina</surname><given-names>M</given-names></name><name><surname>Massawe</surname><given-names>A</given-names></name><name><surname>Lyamuya</surname><given-names>E</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Prevention of mother-to-child transmission of HIV-1 through
breastfeeding by treating mothers with triple antiretroviral therapy in Dar
es Salaam, Tanzania: the Mitra Plus study.</article-title>
<source>J Acquir Immune Defic Syndr</source>
<volume>52</volume>
<fpage>406</fpage>
<lpage>416</lpage>
<pub-id pub-id-type="pmid">19730269</pub-id></element-citation></ref><ref id="pmed.1001015-Chasela1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chasela</surname><given-names>CS</given-names></name><name><surname>Hudgens</surname><given-names>MG</given-names></name><name><surname>Jamieson</surname><given-names>DJ</given-names></name><name><surname>Kayira</surname><given-names>D</given-names></name><name><surname>Hosseinipour</surname><given-names>MC</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Maternal or infant antiretroviral drugs to reduce HIV-1
transmission.</article-title>
<source>N Engl J Med</source>
<volume>362</volume>
<fpage>2271</fpage>
<lpage>2281</lpage>
<pub-id pub-id-type="pmid">20554982</pub-id></element-citation></ref><ref id="pmed.1001015-deVincenzi1"><label>22</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>de Vincenzi</surname><given-names>I</given-names></name></person-group>
<year>2009</year>
<article-title>Triple-antiretroviral (ARV) prophylaxis during pregnancy and
breastfeeding compared to short-ARV prophylaxis to prevent mother-to-child
transmission of HIV-1 (MTCT): the Kesho Bora randomized controlled clinical
trial in five sites in Burkina Faso, Kenya.</article-title>
<comment>In: Proceedings of the 2009 International AIDS Society Conference; Cape
Town, South Africa</comment>
</element-citation></ref><ref id="pmed.1001015-Peltier1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peltier</surname><given-names>CA</given-names></name><name><surname>Ndayisaba</surname><given-names>GF</given-names></name><name><surname>Lepage</surname><given-names>P</given-names></name><name><surname>van Griensven</surname><given-names>J</given-names></name><name><surname>Leroy</surname><given-names>V</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Breastfeeding with maternal antiretroviral therapy or formula
feeding to prevent HIV postnatal mother-to-child transmission in
Rwanda.</article-title>
<source>AIDS</source>
<volume>23</volume>
<fpage>2415</fpage>
<lpage>2423</lpage>
<pub-id pub-id-type="pmid">19730349</pub-id></element-citation></ref><ref id="pmed.1001015-Shapiro1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>RL</given-names></name><name><surname>Hughes</surname><given-names>MD</given-names></name><name><surname>Ogwu</surname><given-names>A</given-names></name><name><surname>Kitch</surname><given-names>D</given-names></name><name><surname>Lockman</surname><given-names>S</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Antiretroviral regimens in pregnancy and breast-feeding in
Botswana.</article-title>
<source>N Engl J Med</source>
<volume>362</volume>
<fpage>2282</fpage>
<lpage>2294</lpage>
<pub-id pub-id-type="pmid">20554983</pub-id></element-citation></ref><ref id="pmed.1001015-Burr1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burr</surname><given-names>CK</given-names></name><name><surname>Lampe</surname><given-names>MA</given-names></name><name><surname>Corle</surname><given-names>S</given-names></name><name><surname>Margolin</surname><given-names>FS</given-names></name><name><surname>Abresh</surname><given-names>C</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>An end to perinatal HIV: success in the US requires ongoing and
innovative efforts that should expand globally.</article-title>
<source>J Public Health Policy</source>
<volume>28</volume>
<fpage>249</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="pmid">17585325</pub-id></element-citation></ref><ref id="pmed.1001015-vanEijk1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Eijk</surname><given-names>AM</given-names></name><name><surname>Bles</surname><given-names>HM</given-names></name><name><surname>Odhiambo</surname><given-names>F</given-names></name><name><surname>Ayisi</surname><given-names>JG</given-names></name><name><surname>Blokland</surname><given-names>IE</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Use of antenatal services and delivery care among women in rural
western Kenya: a community based survey.</article-title>
<source>Reprod Health</source>
<volume>3</volume>
<fpage>2</fpage>
<pub-id pub-id-type="pmid">16597344</pub-id></element-citation></ref><ref id="pmed.1001015-Morgan1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morgan</surname><given-names>MC</given-names></name><name><surname>Masaba</surname><given-names>RO</given-names></name><name><surname>Nyikuri</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>TK</given-names></name></person-group>
<year>2010</year>
<article-title>Factors affecting breastfeeding cessation after discontinuation
of antiretroviral therapy to prevent mother-to-child transmission of
HIV.</article-title>
<source>AIDS Care</source>
<volume>22</volume>
<fpage>866</fpage>
<lpage>873</lpage>
<pub-id pub-id-type="pmid">20635251</pub-id></element-citation></ref><ref id="pmed.1001015-Kuhn1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>L</given-names></name><name><surname>Aldrovandi</surname><given-names>GM</given-names></name><name><surname>Sinkala</surname><given-names>M</given-names></name><name><surname>Kankasa</surname><given-names>C</given-names></name><name><surname>Semrau</surname><given-names>K</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Effects of early, abrupt weaning on HIV-free survival of children
in Zambia.</article-title>
<source>N Engl J Med</source>
<volume>359</volume>
<fpage>130</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="pmid">18525036</pub-id></element-citation></ref><ref id="pmed.1001015-Zeh1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeh</surname><given-names>C</given-names></name><name><surname>Weidle</surname><given-names>PJ</given-names></name><name><surname>Nafisa</surname><given-names>L</given-names></name><name><surname>Lwamba</surname><given-names>HM</given-names></name><name><surname>Okonji</surname><given-names>J</given-names></name><etal/></person-group>
<year>2011</year>
<article-title>HIV-1 drug resistance emergence among breastfeeding infants born
to HIV-infected mothers taking triple-antiretroviral prophylaxis for
prevention of mother-to-child transmission.</article-title>
<source>PLoS Med</source>
<volume>8</volume>
<fpage>e1000430</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000430">10.1371/journal.pmed.1000430</ext-link></comment>
<pub-id pub-id-type="pmid">21468304</pub-id></element-citation></ref><ref id="pmed.1001015-Ouyang1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>DW</given-names></name><name><surname>Brogly</surname><given-names>SB</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Shapiro</surname><given-names>DE</given-names></name><name><surname>Hershow</surname><given-names>RC</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Lack of increased hepatotoxicity in HIV-infected pregnant women
receiving nevirapine compared with other antiretrovirals.</article-title>
<source>AIDS</source>
<volume>24</volume>
<fpage>109</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="pmid">19926957</pub-id></element-citation></ref><ref id="pmed.1001015-Brooks1"><label>31</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Brooks</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name><name><surname>Masaba</surname><given-names>R</given-names></name><name><surname>Amornkul</surname><given-names>P</given-names></name><name><surname>Mwaengo</surname><given-names>D</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Neutropenia in HIV-infected Kenyan women receiving antiretroviral
therapy to prevent mother-to-child HIV transmission.</article-title>
<comment>In: Proceedings of the 12th Conference on Retroviruses and
Opportunistic Infections; February; Boston, Massachusetts, United
States</comment>
</element-citation></ref><ref id="pmed.1001015-Ministry1"><label>32</label><element-citation publication-type="book">
<collab>Ministry of Health, Kenya</collab>
<year>2006</year>
<source>Division of Vaccines and Immunization - Multi Year Plan,
2006&#x02013;2010</source>
<publisher-loc>Nairobi</publisher-loc>
<publisher-name>Ministry of Health, Kenya</publisher-name>
</element-citation></ref><ref id="pmed.1001015-WHO4"><label>33</label><element-citation publication-type="other">
<collab>WHO</collab>
<year>2008</year>
<comment>WHO Expert Consultation on new and emerging evidence on the use of
antiretroviral drugs for the prevention of mother-to-child transmission of
HIV. 17&#x02013;19 November, 2008, Geneva: WHO. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/child_adolescent_health/documents/media/pmtct_consultation_2008.pdf">http://www.who.int/child_adolescent_health/documents/media/pmtct_consultation_2008.pdf</ext-link></comment>
</element-citation></ref><ref id="pmed.1001015-WHO5"><label>34</label><element-citation publication-type="book">
<collab>WHO</collab>
<year>2010</year>
<source>Antiretroviral drugs for treating pregnant women and preventing HIV
infection in infants: recommendations for a public health approach</source>
<publisher-loc>Geneva</publisher-loc>
<publisher-name>WHO</publisher-name>
</element-citation></ref><ref id="pmed.1001015-Fowler1"><label>35</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Fowler</surname><given-names>MG</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>IMPAACT P1077: The PROMISE Study (Promoting Maternal and Infant
Survival Everywhere), synopsis.</article-title>
<comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.impaactgroup.org/files/IMPAACT_P1077_Synopsis.doc">http://www.impaactgroup.org/files/IMPAACT_P1077_Synopsis.doc</ext-link></comment>
</element-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>3TC</term><def><p>lamivudine</p></def></def-item><def-item><term>ARV</term><def><p>antiretroviral</p></def></def-item><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>Hb</term><def><p>hemoglobin</p></def></def-item><def-item><term>KiBS</term><def><p>Kisumu Breastfeeding Study</p></def></def-item><def-item><term>NFV</term><def><p>nelfinavir</p></def></def-item><def-item><term>NVP</term><def><p>nevirapine</p></def></def-item><def-item><term>PMTCT</term><def><p>prevention of mother-to-child transmission</p></def></def-item><def-item><term>SAE</term><def><p>serious adverse event</p></def></def-item><def-item><term>ZDV</term><def><p>zidovudine</p></def></def-item></def-list></glossary></back></article>